<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">92678</article-id>
<article-id pub-id-type="doi">10.7554/eLife.92678</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92678.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cancer Biology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9411-3852</contrib-id>
<name>
<surname>Schmassmann</surname>
<given-names>Philip</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4192-5099</contrib-id>
<name>
<surname>Roux</surname>
<given-names>Julien</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dettling</surname>
<given-names>Steffen</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hogan</surname>
<given-names>Sabrina</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shekarian</surname>
<given-names>Tala</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martins</surname>
<given-names>Tomás A.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ritz</surname>
<given-names>Marie-Françoise</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Herter</surname>
<given-names>Sylvia</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bacac</surname>
<given-names>Marina</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7570-3902</contrib-id>
<name>
<surname>Hutter</surname>
<given-names>Gregor</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a6">6</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Brain Tumor Immunotherapy Lab, Department of Biomedicine, University of Basel</institution>, Basel, <country>Switzerland</country></aff>
<aff id="a2"><label>2</label><institution>Bioinformatics Core Facility, Department of Biomedicine, University of Basel</institution>, Basel, Switzerland</aff>
<aff id="a3"><label>3</label><institution>Swiss Institute of Bioinformatics</institution>, Basel, <country>Switzerland</country></aff>
<aff id="a4"><label>4</label><institution>Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich</institution>, Penzberg, <country>Germany</country></aff>
<aff id="a5"><label>5</label><institution>Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zürich</institution>, Schlieren, <country>Switzerland</country></aff>
<aff id="a6"><label>6</label><institution>Department of Neurosurgery, University Hospital Basel</institution>, Basel, <country>Switzerland</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Ng</surname>
<given-names>Tony</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>King's College London</institution>
</institution-wrap>
<city>London</city>
<country>United Kingdom</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Ng</surname>
<given-names>Tony</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>King's College London</institution>
</institution-wrap>
<city>London</city>
<country>United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>Correspondence: <email>p.schmassmann@unibas.ch</email>, <email>gregor.hutter@usb.ch</email></corresp>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2023-11-21">
<day>21</day>
<month>11</month>
<year>2023</year>
</pub-date>
<volume>12</volume>
<elocation-id>RP92678</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2023-09-15">
<day>15</day>
<month>09</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2023-09-26">
<day>26</day>
<month>09</month>
<year>2023</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.06.17.496574"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2023, Schmassmann et al</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Schmassmann et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-92678-v1.pdf"/>
<abstract>
<title>Abstract</title>
<p>Glioblastoma (GBM) harbors a highly immunosuppressive tumor microenvironment (TME) which influences glioma growth. Major efforts have been undertaken to describe the TME on a single-cell level. However, human data on regional differences within the TME remain scarce. Here, we performed high-depth single-cell RNA sequencing (scRNAseq) on paired biopsies from the tumor center, peripheral infiltration zone and blood of five primary GBM patients. Through analysis of &gt; 45’000 cells, we revealed a regionally distinct transcription profile of microglia (MG) and monocyte-derived macrophages (MdMs) and an impaired activation signature in the tumor-peripheral cytotoxic-cell compartment. Comparing tumor-infiltrating CD8<sup>+</sup> T cells with circulating cells identified CX3CR1<sup>high</sup> and CX3CR1<sup>int</sup> CD8<sup>+</sup> T cells with effector and memory phenotype, respectively, enriched in blood but absent in the TME. Tumor CD8<sup>+</sup> T cells displayed a tissue-resident memory phenotype with dysfunctional features. Our analysis provides a regionally resolved mapping of transcriptional states in GBM-associated leukocytes, serving as an additional asset in the effort towards novel therapeutic strategies to combat this fatal disease.</p>
</abstract>

</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>G.H. has equity in, and is a cofounder of Incephalo Inc. S.D., S.H. and M.B. are affiliated with Roche Pharmaceutical Research and Early Development. The authors have no financial interests to declare.</p></notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Additional computational analyses were performed to validate the results and the method section was expanded to describe our approaches in more detail.
Moreover, we revised Figure 5 and included an additional differential abundance analysis in Figure 2.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Glioblastoma (GBM) is a fatal disease without effective long-term treatment options. The current standard of care consists of tumor resection followed by adjuvant chemoradiotherapy resulting in a median overall survival of only 14 months [<xref ref-type="bibr" rid="c1">1</xref>]. One of the hallmarks in GBM progression is the high rate of neovascularization. The GBM-induced aberrant vessels not only nourish glioma cells, but also provide a specialized niche for tumor-associated stromal and immune cells such as monocyte-derived macrophages (MdMs), yolk sac-derived microglia (MG) (together termed glioma-associated macrophages/microglia, GAMs), and peripheral adaptive immune cells. This immune tumor microenvironment (iTME) paradoxically acts in an immunosuppressive manner and promotes tumor progression [<xref ref-type="bibr" rid="c2">2</xref>]. For example, clinical trials of systemic T cell checkpoint blockade showed only disappointing results [<xref ref-type="bibr" rid="c3">3</xref>, <xref ref-type="bibr" rid="c4">4</xref>], which was attributed in part to the immunosuppressive components of the GBM iTME. The origin of GAMs, infiltration of peripherally derived macrophages across the blood-brain-barrier (BBB) or recruitment of tissue-resident MG to the tumor site, as well as their contribution to gliomagenesis are studied intensively [<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c5">5</xref>–<xref ref-type="bibr" rid="c7">7</xref>]. Hence, major efforts have been undertaken to describe the GBM iTME on a single cell level [<xref ref-type="bibr" rid="c5">5</xref>, <xref ref-type="bibr" rid="c6">6</xref>, <xref ref-type="bibr" rid="c8">8</xref>], or dissect the composition and changes upon disease stages, recurrence and immunotherapy specifically within the GAM compartment [<xref ref-type="bibr" rid="c9">9</xref>–<xref ref-type="bibr" rid="c11">11</xref>]. However, human data on the composition of the iTME in different tumor regions (contrast enhancing tumor center versus peripheral infiltration zone) remain scarce [<xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref>].</p>
<p>To study the region-dependent cellular diversity within individual GBMs, we performed single-cell RNA sequencing (scRNA-seq) on patient-matched biopsies from the tumor center and the peripheral infiltration zone of five primary GBM patients. Additionally, peripheral blood mononuclear cells (PBMC) of the same patients were included to explore the transcriptional changes occurring during tumor infiltration of circulating immune cells.</p>
<p>Our analysis revealed a regionally distinct transcription profile of MG and MdMs and an impaired activation signature in the tumor-peripheral cytotoxic-cell compartment. Comparing tumor-infiltrating CD8<sup>+</sup> T cells with PBMC-derived, identified CX3CR1<sup>high</sup> and CX3CR1<sup>int</sup> CD8<sup>+</sup> T cells with effector and memory phenotype, respectively, enriched in blood but absent in the iTME. Tumor CD8<sup>+</sup> T cells displayed features of tissue-resident memory T cells and were characterized by an exhaustion phenotype. This work provides a regionally-resolved map of transcriptional states in glioma-associated cell types complemented by patient-matched PBMCs, dissecting the composition and molecular diversity of the iTME in GBM.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>scRNA-seq analysis of paired tumor center, periphery and PBMC samples</title>
<p>Fresh, neurosurgically resected tissue from five primary, treatment naïve GBM patients were harvested (<xref rid="fig1" ref-type="fig">Figure 1A</xref>, Supplementary File 1). According to the 2021 WHO Classification of Tumors of the Central Nervous System [<xref ref-type="bibr" rid="c14">14</xref>], in which the term glioblastoma designates only IDH-wildtype grade 4 tumors, we will hence use the term grade 4 glioma, as we included as well IDH-mutant grade 4 tumors (Supplementary File 1). The tumor center was defined as contrast enhancing, whereas the tumor periphery was defined as T2 hyperintense by magnetic resonance imaging (MRI)-guided, navigated surgical resection (<xref rid="fig1" ref-type="fig">Figure 1B</xref>). Increased cellular density of the center vs. periphery samples was confirmed by nuclear DAPI staining on matched histological micrographs of the resected tissue specimens used for scRNA-seq (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). As outlined in <xref rid="fig1" ref-type="fig">Figure 1A</xref>, we separately processed patient tumor and blood samples and enriched them for immune cells by fluorescence-activated cell sorting (FACS) (Figure 1 – figure supplement 1A and 1B). The three samples per patient (center, periphery and PBMC) were loaded on different wells of a 10x Genomics Chromium system for a targeted recovery of 10,000 cells. Due to technical issues cells from the center sample of patient BTB 609 could not be collected.</p>
<p>In total we analyzed 45,466 cells that passed initial quality control and filtering, comprising 8,254 cells from tumor center, 5,954 cells from tumor periphery and 31,258 PBMCs, with 6,354 to 10,957 cells per patient (Supplementary File 2; Figure 1 – figure supplement 1C-1E, Supplementary File 3). All cells were projected onto a two dimensions <italic>t</italic>-distributed stochastic neighbor embedding (tSNE) [<xref ref-type="bibr" rid="c15">15</xref>]. As we observed a good overlap of cells across patients for most of the dataset (see Methods) (Figure 1 – figure supplement 2B – 2F), we chose not to perform any correction for patient-specific effects. Using hierarchical clustering, the cells were partitioned into clusters (Figure 2 – figure supplement 1A, 1B) which were then annotated into nine distinct cell types for the immune subset, including two transcriptionally distinct MG subsets (MG_1 and MG_2) and four cell types for the CD45 negative subset (<xref rid="fig2" ref-type="fig">Figure 2A</xref>; Figure 2 – figure supplement 1C, 1D; Supplementary File 3).</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1</label>
<caption><title>Single-cell RNA-seq of cells from tumor center, periphery and blood.</title>
<p><bold>(A)</bold> Experimental workflow for single-cell analysis of cells isolated from tumor center, periphery and peripheral blood mononuclear cells (PBMC), including fluorescent-activated cell sorting and 3’-scRNA-seq. (<bold>B)</bold> Axial T1 with contrast (left) and T2 (right) MRI brain in a patient with a left temporal GBM. Fresh tumor biopsies were taken according to neuronavigation (green cross). The tumor center was defined as contrast enhancing, whereas the tumor periphery was defined as T2 hyperintense. (<bold>C)</bold> Nuclear DAPI staining of resected tissue specimens. 40x magnification (scale bar = 20 μm). n = 3 patients, 4 field of view (FOV) per patient. Statistics: ***<italic>p</italic> &lt; 0.001, two-tailed Mann Whitney U test (Figure 1 – source data 1).</p></caption>
<graphic xlink:href="496574v2_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2</label>
<caption><title>Single-cell RNA-seq analysis identifies main immune cell populations.</title>
<p><bold>(A)</bold> Dimensionally reduced tSNE projection of the scRNAseq data showing the annotated cell types. (<bold>B)</bold> Heatmap displaying centered and scaled normalized average expression values of characteristic cell-type specific genes used to annotate clusters. Columns are ordered by site and cell type, and rows show centered and scaled expression values, hierarchically clustered. Heatmap displaying genes whose expression is most specific to each cell type is shown in Figure 2 – figure supplement 2. (<bold>C)</bold> Principal component analysis of pseudo-bulk scRNAseq samples aggregated by patient and cell type. Symbols represent individual patients and cell lineage is displayed by different colors. (<bold>D)</bold> Relative frequencies of immune populations among leukocytes between tumor center and periphery. Symbols represent individual patients and paired samples are indicated by connecting lines. <italic>P-</italic>values were calculated using <italic>diffcyt-DA-voom</italic> method (Figure 2 – source data 1). (<bold>E-G</bold>) Differential abundance testing of the tumor innate immune compartment (<bold>E</bold>) using the <italic>miloR</italic> package which tests the abundance of each neighborhood of cells separately between tumor center und periphery (<bold>F, G</bold>).</p></caption>
<graphic xlink:href="496574v2_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>In more detail, our annotation strategy made use of the relative expression patterns of known marker genes (<xref rid="fig2" ref-type="fig">Figure 2B</xref>), and of cluster-specific genes (Figure 2 – figure supplement 2). Additionally, unbiased cell-type annotation using whole-transcriptome comparisons to reference bulk and single-cell datasets was performed with the <italic>SingleR</italic> package. We used as reference (i) a public bulk RNA-seq dataset of sorted immune cell types from human PBMC samples [<xref ref-type="bibr" rid="c16">16</xref>], which helped in identifying the major immune cell lineages: B cells, CD4<sup>+</sup> and CD8<sup>+</sup> T cells, dendritic cells (DCs), monocytes and NK cells (Figure 2 – figure supplement 1E). (ii) A bulk RNA-seq dataset of sorted immune cell types from the TME of human gliomas [<xref ref-type="bibr" rid="c5">5</xref>] was helpful to separate GBM-associated CD4<sup>+</sup> and CD8<sup>+</sup> T cells, as well as microglia and MdMs (Figure 2 – figure supplement 1F). (iii) A 10X genomics scRNA-seq dataset of the innate immune TME of seven newly diagnosed GBM patients [<xref ref-type="bibr" rid="c9">9</xref>] confirmed the annotation of the innate immune subset (Figure 2 – figure supplement 1I), which was also supported by a microglia and a macrophage signature scores defined using gene lists obtained from [<xref ref-type="bibr" rid="c7">7</xref>] (Figure 2 – figure supplement 1J, 1K). (v) Finally a Smartseq2 scRNA-seq dataset of <italic>IDH1<sup>wt</sup></italic> tumors [<xref ref-type="bibr" rid="c17">17</xref>] was used to characterize the CD45<sup>neg</sup> population (Figure 2 – figure supplement 1N).</p>
<p>To perform a differential expression analysis between tumor sites, we stratified the analysis by cell type to decrease the influence of differential abundance patterns (analyzed separately, see below). A principal component analysis (PCA) on the pseudo-bulk aggregated samples (see Methods) confirmed that the major source of variation was due to differences between lymphoid, MG/myeloid cells, and CD45<sup>-</sup> cells (PCs 1 and 2; <xref rid="fig2" ref-type="fig">Figure 2C</xref>). There was no clear association to the <italic>IDH1</italic> status of patients on these or deeper components. However, our study was neither designed nor powered to find regional signatures within the iTME depending on <italic>IDH1</italic> status, but rather to identify common transcriptional differences within the iTME between tumor center, periphery and PBMC of <italic>IDH1<sup>wt</sup></italic> and <italic>IDH1<sup>mut</sup></italic> grade 4 glioma.</p>
<p>Differential abundance analysis between tumor center and periphery did not reveal significant changes, but some populations displayed suggestive differences: the abundance of both CD4<sup>+</sup> T cell and monocytic clusters increased in periphery compared to center, while the abundance of MdM clusters decreased (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). This has been observed by others as well [<xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c18">18</xref>]. Testing the abundance at a finer scale with <italic>miloR</italic> provided us interesting insights. Indeed, within the innate immune population (<xref rid="fig2" ref-type="fig">Figure 2E</xref>) we confirmed the decreased abundance of MdMs in the tumor periphery and noticed an increased abundance of the MG_1 subset of MG in the tumor periphery. (<xref rid="fig2" ref-type="fig">Figure 2F</xref>, 2G).</p>
</sec>
<sec id="s2b">
<title>MG display regionally resolved transcriptional profiles that differ from those of DCs and MdMs</title>
<p>Differential expression analysis between MG from tumor center and periphery revealed downregulation of inflammatory-related genes in the peripheral MG (<italic>FCGBP</italic> and <italic>CCL20</italic>), downregulation of genes associated with canonical interferon (IFN) responses (<italic>IFI6, IFI27, STAT1, ISG15)</italic>, and cell proliferation (<italic>STMN1</italic>) as well as downregulation of scavenger receptor gene <italic>CD163</italic> (<xref rid="fig3" ref-type="fig">Figure 3A</xref> and Supplementary File 4). The latter was shown to have a potential role in the phagocytic response of MG to beta-amyloid depositions identified in single-nucleus RNA-seq of postmortem human brain[<xref ref-type="bibr" rid="c19">19</xref>].</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3</label>
<caption><title>MG display regionally resolved transcriptional profiles that differ from those of DCs and MdMs.</title>
<p><bold>(A)</bold> Microglia cluster highlighted on tSNE map and scatterplots showing differentially expressed genes (FDR&lt;5%, indicated by blue and yellow) in Microglia (MG) cells from tumor periphery versus center. Volcano plot showing <italic>p</italic> value versus fold-change (left) and MA plot showing fold-change versus mean expression (right). For a complete list of differentially expressed genes per cell cluster between tumor periphery and center, please refer to Supplementary File 4. <bold>(B)</bold> Heatmap representation of Gene set enrichment analysis (GSEA) results between peripheral and center microglia using Gene Ontology (GO) collection (Biological Processes). The fraction of overlap between gene sets is calculated as Jaccard coefficient of overlap between the gene sets. <bold>(C, D)</bold> Heatmap representation of GSEA of DCs <bold>(C)</bold> and monocytederived macrophages (MdMs) <bold>(D)</bold> from tumor periphery versus tumor center using Hallmark collection of major biological categories. <bold>(E)</bold> Unsupervised hierarchical sub-clustering of the MG population revealed two transcriptionally distinct subsets of MG, termed MG_1 and MG_2, displayed on the tSNE map. <bold>(F)</bold> Heatmap displaying the cluster-specific genes identifying MG_1 subcluster. Columns are ordered by site and cell type, and rows show centered and scaled normalized average expression values, hierarchically clustered. A complete list of cluster specific genes for MG_1 and MG_2 subcluster is provided in Supplementary File 5. <bold>(G)</bold> Heatmap representation of GSEA between MG_1 and MG_2 subclusters using Hallmark collection of major biological categories. <bold>(H)</bold> Heatmap displaying previously described reactivity markers of MG. Columns are ordered by site and cell type, and rows show centered and scaled normalized average expression values, hierarchically clustered.</p></caption>
<graphic xlink:href="496574v2_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Among many upregulated genes whose function is not yet known, we found Inhibitor of DNA-Binding 1, also known as Inhibitor of Differentiation 1 (<italic>ID1</italic>) to be increased in the peripheral MG (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). ID1 is well described in GBM progression, treatment resistance and glioma stem cell biology [<xref ref-type="bibr" rid="c20">20</xref>]. However, new evidence has emerged, linking <italic>ID1</italic> to suppression of the anti-tumor immune response in the myeloid compartment and promoting tumor progression [<xref ref-type="bibr" rid="c21">21</xref>].</p>
<p>To further explore the underlying biological processes differing between MG in the two compartments, we conducted a gene set enrichment analysis (GSEA) on the results of the differential expression analysis using Gene Ontology (GO) database (Biological Processes). This revealed overall a significant downregulation of GO categories involved in antigen processing and presentation via MHC-I and MHC-II in the peripheral MG relative to the center MG, as well as downregulation of amino acid metabolism and TNF-α signaling pathway (<xref rid="fig3" ref-type="fig">Figure 3B</xref>), which supported the conclusion of an impaired activation state of peripheral MG.</p>
<p>When comparing the transcriptional profiles of the other innate immune phagocytic populations, DCs and MdMs, we observed for both cell types upregulation of pro-inflammatory related gene sets in the tumor periphery compared to tumor center (<xref rid="fig3" ref-type="fig">Figure 3C</xref>, 3D, Figure 3 - figure supplement 1A, 1B and Supplementary File 4). Within DCs, the induced pro-inflammatory phenotype was also observed when comparing DCs from tumor periphery to PBMC-derived ones (Figure 3 -figure supplement 1C, 1D and Supplementary File 6). Taken together, DCs and MdMs seem to have a proinflammatory phenotype in the glioma periphery as opposed to MG. However, they are less abundant there, at least as far as MdMs are concerned (<xref rid="fig2" ref-type="fig">Figure 2E</xref>-<xref rid="fig2" ref-type="fig">2G</xref>).</p>
</sec>
<sec id="s2c">
<title>The iTME of grade 4 glioma harbors two transcriptionally distinct MG subpopulations</title>
<p>Unsupervised hierarchical sub-clustering of the MG population revealed two transcriptionally distinct iTME MG subsets, which we termed MG_1 and MG_2, respectively (<xref rid="fig3" ref-type="fig">Figure 3E</xref>, Figure 3 – figure supplement 1E and Supplementary File 5). The MG_1 cluster was highly enriched for the activator protein-1 (AP-1) family of transcription factors including <italic>FOS, FOSB, JUN, JUNB, MAF</italic> and <italic>MAFB</italic> (<xref rid="fig3" ref-type="fig">Figure 3F</xref> and Supplementary File 5), which convey a surveilling phenotype to adult MG, but are also involved in numerous processes including cell growth, differentiation and immune activation [<xref ref-type="bibr" rid="c22">22</xref>]. Specifically, <italic>FOSB</italic> gene products were implicated in the excitotoxic MG activation by regulating complement C5a receptor expression [<xref ref-type="bibr" rid="c23">23</xref>]. Yet, concomitant upregulation of anti-inflammatory Krüppel-like factor 2 (<italic>KLF2</italic>) [<xref ref-type="bibr" rid="c24">24</xref>] and Dual Specificity Protein Phosphatase 1 (<italic>DUSP1</italic>), an inhibitor of innate inflammation by negatively regulating the mitogen-activated protein kinase (MAPK) pathway [<xref ref-type="bibr" rid="c25">25</xref>], together with increased expression of anti-proliferative genes like <italic>RHOB, BTG1</italic> and <italic>BTG2</italic> paint a more complex picture of these cells. Particularly, <italic>BTG1</italic> was identified as an activation-induced apoptotic sensitizer in MG after exposure to inflammatory stimuli [<xref ref-type="bibr" rid="c26">26</xref>], serving as an autoregulatory mechanism and possibly hinting towards an exhausted state in these MG_1 cells. GSEA for differences between MG_1 and MG_2 clusters using the MSigDB Hallmark collection of major biological pathways [<xref ref-type="bibr" rid="c27">27</xref>] revealed downregulation of many MG effector functions in the MG_1 population including (1) inflammation (“Complement”, “Allograft Rejection”, “Reactive Oxygen Species Pathway”), (2) immune cell activation (“IFN-α Response”, “IFN-ψ Response”, “IL6 JAK STAT3 Signaling”) and (3) immunometabolism (“Fatty Acid Metabolism”, Oxidative Phosphorylation”, “Glycolysis”) (<xref rid="fig3" ref-type="fig">Figure 3G</xref>). As we examined the expression of previously described reactivity markers of MG including <italic>C1QA</italic>, <italic>FCGR1A, CD14, HLA-DRA</italic>, <italic>TREM2 and</italic> Ferritin (<italic>FTH1</italic>) [<xref ref-type="bibr" rid="c28">28</xref>–<xref ref-type="bibr" rid="c31">31</xref>] (<xref rid="fig3" ref-type="fig">Figure 3H</xref> and Figure 3 – figure supplement 1F), and established MG homeostatic genes like <italic>CX3CR1, HEXB</italic> and <italic>SPI1</italic> (PU.1) (Supplementary File 5), we noted a reduced expression of these genes in the MG_1 cluster compared to MG_2 cells, while the anti-inflammatory transcription factors <italic>NR4A1</italic> [<xref ref-type="bibr" rid="c32">32</xref>] <italic>NR4A2</italic> [<xref ref-type="bibr" rid="c33">33</xref>] were highly upregulated (Figure 3 – figure supplement 1G). Additionally, when comparing the distribution of MG subsets between sites among total MG, we observed an increased abundance of MG_1 cells in the tumor periphery, which might at least partially explain the previously observed impaired activation state of total peripheral MG (Figure 3 – figure supplement 1H). To rule out this explanation we stratified the differential expression analysis between tumor periphery and center by MG subtype and observed similar genes downregulated in the tumor periphery in each subtype (e.g. <italic>CCL20, FCGBP</italic>) (Supplementary File 5), arguing that the non-reactive phenotype is a common feature for all peripheral MG and is not only driven by a differential abundance pattern of one MG subpopulation relative to the other.</p>
</sec>
<sec id="s2d">
<title>The tumor peripheral cytotoxic cell compartment exhibits an impaired activation signature</title>
<p>Next, we investigated the regional differences in the lymphoid compartment composed of CD4<sup>+</sup> and CD8<sup>+</sup> T cells and natural killer (NK) cells. We observed only very few significant changes in the transcriptomic profiles of CD4<sup>+</sup> T cells between tumor center and periphery (Figure 4 – figure supplement 1A and Supplementary File 4). Yet, comparing peripheral CD8<sup>+</sup> T cells with CD8<sup>+</sup> T cells from tumor center revealed 110 differentially expressed genes (43 genes upregulated and 67 genes downregulated) (Figure 4A and Supplementary File 4). Many downregulated genes in the peripheral CD8<sup>+</sup> T cells associated with canonical IFN responses (<italic>IFI6, IFI27, MX1, STAT1, EPSTI1 PARP9, ISG15)</italic> [<xref ref-type="bibr" rid="c34">34</xref>] cell proliferation (<italic>STMN1, CENPF, HELLS, NUSAP1</italic> and <italic>DNPH1</italic>) and T cell co-stimulation (<italic>CD28, TMIGD2</italic> (CD28H), <italic>TNFRSF4</italic> (OX40), <italic>CD27</italic> and <italic>TNFRSF18</italic> (GITR)) (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). Contrary to our expectations, we saw upregulation of <italic>CTLA4</italic> in the center CD8<sup>+</sup> T cells which acts as a negative costimulatory molecule. However, unlike other costimulatory receptors, such as CD27 and CD28, CTLA-4 is not constitutively expressed on T lymphocytes [<xref ref-type="bibr" rid="c35">35</xref>]. but only induced following T cell activation, along with positive costimulatory molecules such as OX40 and GITR. In addition, upregulation of CTLA-4 requires entry into the cell cycle [<xref ref-type="bibr" rid="c35">35</xref>]. In line with that, we detected an upregulation of proliferative genes in center CD8<sup>+</sup> T cells. In summary, CTLA-4 induction in center CD8<sup>+</sup> T cells rather suggested T cell activation than exhaustion, especially since other inhibitory receptors like <italic>PDCD1</italic> (PD-1)<italic>, LAG3</italic> and <italic>HAVCR2</italic> (TIM-3) were not differentially expressed between sites. Moreover, we did not observe differential expression of genes involved in CD8<sup>+</sup> T cell effector functions like cytotoxicity (e.g., <italic>GZMK, GZMB, KLRG1,</italic> PRF1) or cytokines (e.g., <italic>CCL5, XCL1, XCL2, IL10</italic>). Yet, we noted upregulation of inhibitory genes (<italic>TGFB1</italic> and <italic>FCRL6</italic> [<xref ref-type="bibr" rid="c36">36</xref>]) in the peripheral CD8<sup>+</sup> T cells, suggesting that a pool of activated, proliferating and IFN-responsive CD8<sup>+</sup> T cells is present in the tumor center, however, absent in the tumor periphery.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4</label>
<caption><title>The peripheral cytotoxic cell compartment exhibits an impaired activation signature.</title>
<p><bold>(A, B)</bold> Volcano plots showing differentially expressed genes (FDR corrected <italic>p</italic> value &lt; 0.05, indicated by blue and yellow) in CD8<sup>+</sup> T cells (<bold>A</bold>) and NK cells (<bold>B</bold>) from tumor periphery versus tumor center. Colored rings mark genes belonging to selected GSEA Hallmark or Gene Ontology (GO) pathways as indicated. For a complete list of differentially expressed genes per cell cluster between tumor periphery and center, please refer to Supplementary File 4.</p></caption>
<graphic xlink:href="496574v2_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Similar trends were observed for the peripheral NK cell population with peripherally reduced IFN response (<italic>MX1</italic> and <italic>IFI44L</italic>), and proliferative genes (<italic>STMN1, HELLS, CENPF, PTTG1</italic> and <italic>DNPH1</italic>), downregulated stimulatory receptors (<italic>TMIGD2</italic> (CD28H) and <italic>TNFRSF18</italic> (GITR)), and reduced NF-κB signaling (<italic>NFKB1</italic> and <italic>RELB</italic>) (<xref rid="fig4" ref-type="fig">Figure 4B</xref> and Supplementary File 4). Although, we observed upregulation of key genes associated with NK cell effector function in the periphery (e.g., <italic>FCGR3A</italic> (CD16), <italic>FGFBP2, ITGB2, GZMH</italic> and <italic>KIR2DS4</italic>), increased expression of inhibitory receptors like <italic>LILRB1</italic> and <italic>KLRG1</italic>, the latter especially in co-expression with chemokine receptor <italic>CX3CR1</italic>, identified the peripheral NK cells rather to be terminally differentiated with impaired cytotoxic capabilities [<xref ref-type="bibr" rid="c37">37</xref>]. This was in line with the observed abrogated cytokine activity profile in the peripheral NK cells with reduced expression of key factors like <italic>XCL1, XCL2, LTB</italic> and <italic>CKLF.</italic> In summary, our data revealed an impaired activation signature in the peripheral cytotoxic cell compartment.</p>
</sec>
<sec id="s2e">
<title>CX3CR1 labels a specific CD8<sup>+</sup> T cell population in the circulation of grade 4 glioma patients</title>
<p>Next, we investigated the relationships between circulating CD8<sup>+</sup> T cells and those from the tumor milieu and, more specifically, the peripheral, infiltration zone characterized by an abrogated CD8<sup>+</sup> T-cell IFN response and activation signature. Strikingly, there were large transcriptomic differences between PBMC and periphery CD8<sup>+</sup> T cells (<xref rid="fig5" ref-type="fig">Figure 5A</xref>), with 1,417 differentially expressed genes (864 genes upregulated in the tumor periphery and 553 genes upregulated in PBMC) (<xref rid="fig5" ref-type="fig">Figure 5B</xref>, Supplementary File 6).</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5</label>
<caption><title>CX3CR1 labels a specific CD8+ T cell population in the circulation of grade 4 glioma patients.</title>
<p><bold>(A)</bold> CD8<sup>+</sup> T cell cluster highlighted on tSNE map (left). CD8<sup>+</sup> T cell cluster colored by site of origin (right). (<bold>B)</bold> Volcano plot showing differentially expressed genes (FDR corrected <italic>p</italic> value &lt; 0.05, indicated by blue and green) in CD8<sup>+</sup> T cells from tumor-periphery versus PBMC. For a complete list of differentially expressed genes per cell cluster between tumor periphery and PBMC, please refer to Supplementary File 6. (<bold>C)</bold> Frequency of CX3CR1<sup>+</sup> CD8<sup>+</sup> T cells among all CD8<sup>+</sup> T cells in flow cytometry data (Figure 5 – source data 1). (<bold>D</bold>) Unsupervised hierarchical sub-clustering of CD8<sup>+</sup> T cells from PBMC and Periphery revealed two transcriptionally distinct subsets of PBMC CD8<sup>+</sup> T cells, displayed on the tSNE map. (<bold>E)</bold> Expression of <italic>CX3CR1</italic> overlaid on tSNE CD8<sup>+</sup> T cell cluster. (<bold>F)</bold> Expression of genes associated with effector memory phenotype overlaid on tSNE CD8<sup>+</sup> T cell cluster. Displayed genes are significantly, differentially expressed genes (DEGs) between tumor periphery and PBMC, as identified by differential gene expression analysis shown in panel (B). (<bold>G)</bold> Expression of selected genes associated with naive phenotype overlaid on tSNE CD8<sup>+</sup> T cell cluster (<bold>H)</bold> Gating procedure applied to identify CD3<sup>+</sup> CD8<sup>+</sup> naïve, T effector cells (T<sub>eff</sub>), effector memory (T<sub>em</sub>), peripheral memory (T<sub>pm</sub>) and central memory (T<sub>cm</sub>), eluted from PBMCs. (<bold>I)</bold> Expression of CX3CR1 in PBMC CD8<sup>+</sup> T cell subpopulations identified in (H) (Figure 5 – source data 2). <italic>n</italic> = 6 donors (<bold>C</bold>), <italic>n</italic> = 11 donors (<bold>I</bold>). Statistics: Wilcoxon matched-pairs signed rank test (<bold>C</bold>); repeated measures oneway ANOVA with post-hoc Šidák’s correction for multiple comparisons (<bold>I</bold>). *<italic>p</italic> ≤ 0.05, **<italic>p</italic> ≤ 0.01, ***<italic>p</italic> ≤ 0.001, ****<italic>p</italic> ≤ 0.0001, no brackets indicate no significant difference.</p></caption>
<graphic xlink:href="496574v2_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Interestingly, one of the key genes upregulated in PBMC CD8<sup>+</sup> T cells was the chemokine receptor <italic>CX3CR1</italic> (<xref rid="fig5" ref-type="fig">Figure 5B</xref>). Flow cytometry of an additional matched glioma grade 4 patient cohort confirmed an increased abundance of CX3CR1<sup>+</sup> CD8<sup>+</sup> T cells in PBMC compared to almost absent CX3CR1<sup>+</sup> CD8<sup>+</sup> T cells in tumor periphery (<xref rid="fig5" ref-type="fig">Figure 5C</xref>, Figure 5 – figure supplement 1A, Supplementary File 1). Unsupervised hierarchical sub-clustering of CD8<sup>+</sup> T cells revealed that <italic>CX3CR1</italic> expression labelled a specific subpopulation among PBMC CD8<sup>+</sup> T cells (<xref rid="fig5" ref-type="fig">Figure 5D</xref>, 5E).</p>
<p>Recently, expression of CX3CR1 was demonstrated to distinguish memory CD8<sup>+</sup> T cells with cytotoxic effector function in healthy donors and different inflammation related conditions [<xref ref-type="bibr" rid="c38">38</xref>–<xref ref-type="bibr" rid="c41">41</xref>]. Further characterization of classical central memory (T<sub>cm</sub>) and effector memory (T<sub>em</sub>) populations by varying surface expression levels of CX3CR1 identified a novel CX3CR1<sup>int</sup> subpopulation, termed peripheral memory (T<sub>pm</sub>). T<sub>pm</sub> cells underwent frequent homeostatic divisions, re-acquired CD62L, homed to lymph nodes, and predominantly surveyed peripheral tissues compared to T<sub>cm</sub> and T<sub>em</sub> [<xref ref-type="bibr" rid="c39">39</xref>]. In our dataset, the circulating CX3CR1<sup>+</sup> CD8<sup>+</sup> T cells indeed displayed a core signature of memory CD8<sup>+</sup> T cells with effector function, comprising expression of LFA-1 (<italic>IGAL-ITGB2</italic>)<italic>, TBX2</italic> (Tbet), <italic>SELL</italic> (CD62L)<italic>, GZMB</italic> (Granzyme B) and <italic>PRF1</italic> (Perforin 1) (<xref rid="fig5" ref-type="fig">Figure 5F</xref>), separating them from circulating <italic>CX3CR1<sup>-</sup> CD28<sup>high</sup></italic>, <italic>IL7R<sup>high</sup></italic> and <italic>CD27<sup>high</sup></italic> naïve CD8<sup>+</sup> T cells (<xref rid="fig5" ref-type="fig">Figure 5G</xref> and Figure 5 – figure supplement 1B). Flow cytometric analysis confirmed T<sub>eff</sub> to be CX3CR1<sup>high</sup>, with negligible expression levels in the naïve CD8<sup>+</sup> T cells, whereas the identified memory CD8<sup>+</sup> T cells (T<sub>em</sub> and T<sub>pm</sub>) were CX3CR1<sup>int</sup> (<xref rid="fig5" ref-type="fig">Figure 5H</xref>, 5I). Collectively, surface expression analysis of CX3CR1 identified a subset of CX3CR1<sup>high</sup> T<sub>eff</sub> and CX3CR1<sup>int</sup> memory (T<sub>em</sub>, T<sub>pm</sub>) CD8<sup>+</sup> T cells in the circulation of grade 4 glioma patients with potentially elevated tissue surveilling properties in the case of T<sub>pm</sub>, which are, however, largely absent in the tumor microenvironment.</p>
</sec>
<sec id="s2f">
<title>CD8<sup>+</sup> T cells in the tumor periphery share features with tissue-resident memory T cells (T<sub>rm</sub>)</title>
<p>We next examined the differing transcriptional and surface-specific features between tumor infiltrating and circulating CD8<sup>+</sup> T cells. Surface staining for CD45RA and CD45RO, discriminating naïve/effector from memory T cells, attributed a predominant CD45RO<sup>+</sup> memory phenotype to the tumor infiltrating CD8<sup>+</sup> T cells (<xref rid="fig6" ref-type="fig">Figure 6A</xref>, 6B). Interrogation of the transcriptomic profile of these cells revealed a key marker expression signature consistent with tissue-resident memory T cells (T<sub>rm</sub>): Expression of cellular adhesion molecules (integrins) <italic>ITGA1</italic> (CD49a) and <italic>ITGAE</italic> (CD103), tissue retention marker <italic>CD69</italic>, chemokine receptors implicated in tissue-homing <italic>CXCR3, CXCR6</italic> and <italic>CCR5</italic> [<xref ref-type="bibr" rid="c42">42</xref>] and transcription factors, <italic>ZNF683</italic> (Hobit) and <italic>PRDM1</italic> (Blimp1) as well as reduced expression of <italic>TBX21</italic> (Tbet) and <italic>EOMES</italic> [<xref ref-type="bibr" rid="c43">43</xref>], strongly suggested a T<sub>rm</sub> phenotype for these cells (<xref rid="fig6" ref-type="fig">Figure 6C</xref>, 6D and Figure 6 – figure supplement 1A). Co-expression analysis of paired PBMC and tumor periphery samples using flow cytometry showed that CD69<sup>+</sup> CD103<sup>-</sup> and CD69<sup>+</sup> CD103<sup>+</sup> cells are the dominant CD8<sup>+</sup> T cell populations in the tumor periphery (<xref rid="fig6" ref-type="fig">Figure 6E</xref>, 6F). Combined, these data strongly suggest a T<sub>rm</sub> phenotype for the CD8<sup>+</sup> T cells in the tumor periphery.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6</label>
<caption><title>CD8<sup>+</sup> T cells in the tumor periphery share features with tissue-resident memory T cells (Trm)</title>
<p>(<bold>A)</bold> Representative dot plot of tumor-periphery CD8<sup>+</sup> T cells stained for CD45RA and CD45RO. (<bold>B)</bold> Quantification of tumor-periphery CD8<sup>+</sup> T cells expressing CD45RA or CD45RO (Figure 6 – source data 1). (<bold>C)</bold> Expression of genes associated with tissue-resident memory (T<sub>rm</sub>) phenotype overlaid on tSNE CD8<sup>+</sup> T cell cluster. (<bold>D)</bold> Average expression levels of selected T<sub>rm</sub> markers between CD8<sup>+</sup> T cells from PBMC versus tumor-periphery. Significance testing based on differential gene expression analysis shown in panel (<xref rid="fig5" ref-type="fig">Fig. 5B</xref>) (<bold>E)</bold> Representative dot plots of CD69 and CD103 co-expression in CD8<sup>+</sup> T cells from PBMC and tumor-periphery. (<bold>F)</bold> Quantification of CD69 and CD103 co-expression revealed CD69<sup>-</sup> CD103<sup>-</sup> in PBMC and CD69<sup>+</sup> CD103<sup>-</sup> and CD69<sup>+</sup> CD103<sup>+</sup> in tumor-periphery as the dominant phenotypes (Figure 6 – source data 2). (<bold>G)</bold> Expression of selected markers associated with T cell exhaustion/dysfunction, shown as boxplots between CD8<sup>+</sup> T cell from PBMC and tumorperiphery and overlaid on tSNE CD8<sup>+</sup> T cell cluster. <italic>n</italic> = 6 donors (<bold>B, F</bold>). Statistics: Wilcoxon matched-pairs signed rank test (<bold>B</bold>); repeated measures one-way ANOVA with post-hoc Šidák’s correction for multiple comparisons (<bold>F</bold>). *<italic>p</italic> ≤ 0.05, **<italic>p</italic> ≤ 0.01, ***<italic>p</italic> ≤ 0.001, ****<italic>p</italic> ≤ 0.0001, no brackets indicate no significant difference.</p></caption>
<graphic xlink:href="496574v2_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Previous reports of T<sub>rm</sub> populating the brain in the aftermath of central or peripheral infections concluded that brain T<sub>rm</sub> cells surveil the brain tissue and mediate protection by rapid activation and enhanced cytokine production [<xref ref-type="bibr" rid="c42">42</xref>]. Indeed, CD8<sup>+</sup> T cells in the tumor periphery showed increased expression of genes belonging to costimulatory pathways, including <italic>ICOS, TNFRSF4</italic> (OX40) and <italic>TNFRSF9</italic> (4-1BB) (Figure 6 – figure supplement 1B, Supplementary File 6), albeit accompanied by high levels of inhibitory receptors <italic>PDCD1</italic> (PD-1), <italic>LAG3, HAVCR2</italic> (TIM-3) and <italic>CTLA4</italic> (<xref rid="fig6" ref-type="fig">Figure 6G</xref>). Moreover, expression of genes coding for cytotoxic molecules, including Granzyme B and Perforin 1 were decreased in the peripheral CD8<sup>+</sup> T cells, suggesting a compromised killing capacity of these cells. And lastly, CD8<sup>+</sup> T cells in the tumor periphery exhibited a transcription factor profile of exhausted T cells with high expression of <italic>NR4A1, MAF</italic> and <italic>IRF4</italic> (<xref rid="fig6" ref-type="fig">Figure 6G</xref> and Figure 6 – figure supplement 1C), which were implicated in T cell dysfunction and exhaustion [<xref ref-type="bibr" rid="c44">44</xref>, <xref ref-type="bibr" rid="c45">45</xref>]. Collectively, these data indicate that CD8<sup>+</sup> T cells in the glioma periphery share features with T<sub>rm</sub> cells. However, inhibitory receptor expression, functional molecules and transcriptional signature ascribe an exhausted phenotype to these cells.</p>
<p>Noteworthy, we observed high upregulation of similar genes in the comparison tumor periphery vs. PBMC for CD4<sup>+</sup> T cells as for CD8<sup>+</sup> T cells (Figure 6 – figure supplement 1D). These included transcription factor family <italic>NRA41-3,</italic> identified as key mediator of T cell dysfunction [<xref ref-type="bibr" rid="c45">45</xref>], Dual Specificity Protein Phosphatase 2/4 (<italic>DUSP2, DUSP4</italic>) described as negative regulators of mitogen-activated protein (MAP) kinase superfamily and associated with impaired T cell effector activity [<xref ref-type="bibr" rid="c46">46</xref>] and T cell senescence [<xref ref-type="bibr" rid="c47">47</xref>], and transcription factor <italic>CREM</italic> which was implicated in IL-2 suppression [<xref ref-type="bibr" rid="c48">48</xref>]. These genes could potentially identify pan T cell dysfunction markers within the GBM iTME [<xref ref-type="bibr" rid="c49">49</xref>].</p>
</sec>
<sec id="s2g">
<title>Interrogation of cell-cell interactions revealed critical role of SPP1-mediated crosstalk between MG and lymphocytes in the tumor periphery</title>
<p>We finally investigated cell-cell interactions based on ligand-receptor expression levels using the CellChat platform [<xref ref-type="bibr" rid="c50">50</xref>]. Considering that MG and lymphocytes displayed an impaired activation signature in the tumor periphery, we focused our analysis on the tumor-peripheral crosstalk between these cells (<xref rid="fig7" ref-type="fig">Figure 7A</xref>). This revealed SPP1 (Osteopontin) as a leading potential cell-cell interaction mediator between MG and lymphocytes (<xref rid="fig7" ref-type="fig">Figure 7A</xref> and <xref rid="fig7" ref-type="fig">7B</xref>). MG SPP1<italic>-</italic>mediated signaling was as well among the most significant interactions, when investigating cell-cell communication across all cell types and both sites (Figure 7 – figure supplement 1A, 1B). Further, we found that <italic>SPP1</italic> is mainly expressed by MG rather than glioma cells, contrary to previous reports [<xref ref-type="bibr" rid="c51">51</xref>] (<xref rid="fig7" ref-type="fig">Figure 7C</xref>, Figure 7 – figure supplement 1C, 1D). MG SPP1 conveys different interactions, depending on the recipient cell binding receptor expression profile. The predicted interactions of MG SPP1 with NK cells could be mediated via the integrin complex <italic>ITGA4-ITGB1</italic> (CD49d-CD29) (<xref rid="fig7" ref-type="fig">Figure 7A</xref>, 7C), whereas CD4<sup>+</sup> and CD8<sup>+</sup> T cells exhibited strong interactions with MG via SPP1/CD44 interaction (<xref rid="fig7" ref-type="fig">Figure 7A</xref>, 7B). The SPP1/CD44 axis was recently described to suppress T cell activation and proliferation [<xref ref-type="bibr" rid="c52">52</xref>]. The identified MG SPP1-mediated interactions might represent potential targets to modulate MG-lymphocyte crosstalk in the tumor periphery.</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Figure 7</label>
<caption><title>Cell-cell communication analysis using CellChat reveals critical role for SPP1-mediated crosstalk in tumor periphery.</title>
<p><bold>(A)</bold> Chord diagram showing significant interactions from microglia to lymphocyte cell clusters. The inner bar colors represent the targets that receive signal from the corresponding outer bar. The inner bar size is proportional to the signal strength received by the targets. Chords indicate ligand-receptor pairs mediating interaction between two cell clusters, size of chords is proportional to signal strength of the given ligand-receptor pair. (<bold>B)</bold> Comparison of incoming and outgoing interaction strength allows identification of main senders and receivers. (<bold>C)</bold> Violin plots showing the expression distribution of signaling genes involved in the inferred SPP1 signaling network.</p></caption>
<graphic xlink:href="496574v2_fig7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>In this study, we combined single-cell RNA sequencing and flow cytometry to interrogate the regional leukocyte activation signature in patient-matched biopsies from contrast-enhancing tumor center, infiltrative peripheral rim, and blood PBMCs of grade 4 glioma patients. Our analyses revealed a distinct, regionally dependent transcriptional profile for most of the investigated cell populations. While peripheral MG and cytotoxic cells predominantly displayed an impaired activation signature, MdMs showed pro-inflammatory traits in the tumor periphery, however, were less abundant there compared to the tumor center, which was reported by others as well [<xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref>]. Supplemented with transcriptional analysis of paired PBMC samples, we provide an in-depth characterization of the three main immunological compartments of grade 4 glioma.</p>
<p>Previous studies focused on the description of the TME of grade 4 glioma, which also considered regional differences, yet they focused primarily at neoplastic cells rather than the immune compartment [<xref ref-type="bibr" rid="c12">12</xref>]. Others investigated the differences in the iTME composition between primary and metastatic brain tumors [<xref ref-type="bibr" rid="c5">5</xref>, <xref ref-type="bibr" rid="c6">6</xref>]. Interestingly, the two latter ones reported differences in the iTME composition between <italic>IDH1<sup>wt</sup></italic> and <italic>IDH1<sup>mut</sup></italic> glioma. Of note, both authors included low-grade and even pre-treated recurrent glioma patients into the <italic>IDH1<sup>mut</sup></italic> group, representing a quite heterogenous patient cohort. In this study, we aimed at providing a representative selection of primary, treatment-naïve grade 4 glioma patients including <italic>IDH1<sup>wt</sup></italic> and <italic>IDH1<sup>mut</sup></italic> to identify common transcriptional differences within the iTME between tumor center, periphery and PBMC of grade 4 glioma. How far these regional differences vary between <italic>IDH1<sup>wt</sup></italic> and <italic>IDH1<sup>mut</sup></italic> grade 4 glioma merits further investigation.</p>
<p>We identified a transcriptionally distinct MG subcluster, MG_1, which was enriched in the infiltrative tumor periphery and displayed an anti-inflammatory/non-reactive phenotype. A similar MG subpopulation expressing a comparable gene signature was recently described to be enriched in Alzheimer’s disease patients [<xref ref-type="bibr" rid="c53">53</xref>].</p>
<p>Additionally, the peripheral cytotoxic cell compartment exhibited an impaired activation state, including a downregulated IFN response signature in CD8<sup>+</sup> T cells. Induction of an IFN response state was described as a consequence of T cell receptor-mediated IFN-ψ production, likely serving as an autocrine response and inducing the proliferative program [<xref ref-type="bibr" rid="c34">34</xref>]. Hence, the reduced autocrine IFN-responsive state in the tumor peripheral CD8<sup>+</sup> T cells, together with downregulated proliferative and co-stimulatory genes emphasized their impaired activation in the peripheral infiltration zone. Recently, we showed that the response to immunotherapy in GBM is indeed region dependent. For this, we cultured GBM explants in perfusion bioreactors and treated with anti-CD47, anti-PD1, or their combination which induced an IFN-γ response only in the tumor center, but not periphery [<xref ref-type="bibr" rid="c54">54</xref>]. Adding experimental support to the here described impaired activation signature in the tumor periphery.</p>
<p>By exploring the transcriptional trajectory of CD8<sup>+</sup> T cells from the blood circulation into the immunosuppressive TME of the tumor periphery, we uncovered CX3CR1<sup>high</sup> and CX3CR1<sup>int</sup> effector and memory CD8<sup>+</sup> T cells, respectively, to be highly enriched in the PBMC, but absent in the iTME. Recently, adoptive transfer studies of CX3CR1<sup>+</sup> CD8<sup>+</sup> T cells in a melanoma mouse model significantly suppressed tumor growth [<xref ref-type="bibr" rid="c41">41</xref>]. Others identified increased frequencies of CX3CR1<sup>+</sup> CD8<sup>+</sup> T cells in non-small cell lung and melanoma patients who responded to anti-PD-1 therapy, where these cells exhibited migratory capabilities into the tumor site followed by potent tumor rejection [<xref ref-type="bibr" rid="c40">40</xref>, <xref ref-type="bibr" rid="c41">41</xref>]. Thus, the authors proposed T cell CX3CR1 expression as a predictor of response to ICI therapy. Even though CX3CR1<sup>+</sup> CD8<sup>+</sup> T cells might not be specific to GBM, as they are found in healthy donor and different inflammation related conditions [<xref ref-type="bibr" rid="c38">38</xref>–<xref ref-type="bibr" rid="c41">41</xref>], the absence of these effector and potentially ICI therapy responsive CD8<sup>+</sup> T cells in the glioma TME could serve as an additional explanation for the disappointing outcome of clinical trials using ICI in glioma patients.</p>
<p>The observed T<sub>rm</sub> exhaustion phenotype of the glioma residing CD8<sup>+</sup> T cells was recently reported as well for tumor-infiltrating PD-1<sup>high</sup> CD8<sup>+</sup> T cells in hepatocellular carcinoma [<xref ref-type="bibr" rid="c44">44</xref>]. Whether these glioma-associated CD8<sup>+</sup> T cells really possess tumor-specificity requires further study. Particularly in the light of a recent study by Smolders and colleagues who reported a consistent brain-resident CD8<sup>+</sup> T cell population in a miscellaneous autopsy cohort of patients with neurological disorders excluding brain malignancies (Alzheimer’s disease, Parkinson’s disease, dementia, depression, multiple sclerosis), as well as patients with no known brain disease. These brain-resident CD8<sup>+</sup> T cells displayed a remarkably consistent T<sub>rm</sub> phenotype [<xref ref-type="bibr" rid="c55">55</xref>]. The authors further showed high expression of inhibitory receptors CTLA-4 and PD1 on the brain-resident CD8<sup>+</sup> T<sub>rm</sub> cells, which is in line with the core phenotypic signature of T<sub>rm</sub> cells from other tissues [<xref ref-type="bibr" rid="c56">56</xref>, <xref ref-type="bibr" rid="c57">57</xref>]. Yet, the brain CD8<sup>+</sup> T<sub>rm</sub> cells showed a preserved inflammatory potential with substantial production of IFN-ψ and TNF-α upon <italic>ex vivo</italic> stimulation. They concluded that extensive immune activation with release of highly neurotoxic lytic enzymes, such as perforin and granzyme B, harmfully impacts the brain parenchyma and should be tightly controlled, whilst maintaining the capability to elicit a fast inflammatory response when a neurotropic virus threatens the CNS [<xref ref-type="bibr" rid="c55">55</xref>]. Therefore, inhibitory receptors like PD-1 and CTLA-4 on brain CD8<sup>+</sup> T<sub>rm</sub> cells may support CNS homeostasis by preventing uncontrolled T cell reactivity, and the availability of the receptor ligands may determine their inhibitory effect. While this may represent a well-balanced equilibrium under healthy conditions, the tumor setting leads to its disruption with upregulation of inhibitory ligands like PD-L1 on glioma cells and CD86 on GAMs, leading to the dysfunctional state seen in the glioma-residing CD8<sup>+</sup> T<sub>rm</sub> cells.</p>
<p>Another study comprehensively showed, that peripheral infections generate antigenspecific CD8<sup>+</sup> T<sub>rm</sub> cells in the brain, mediating protection against CNS infections [<xref ref-type="bibr" rid="c42">42</xref>]. These data could implicate that the glioma-associated CD8<sup>+</sup> T cells are devoid of tumor-specific reactivity, but rather represent a pre-existing T cell population generated after peripheral infections, which acquired a dysfunctional state upon glioma formation. To test this hypothesis, further characterization of these cells is required, including analysis of T cell receptor clonality and tumor-specificity by patient-matched T cell/glioma-sphere co-culture assays.</p>
<p>Lastly, our cell-cell interaction analysis revealed signaling pathways between peripheral MG and lymphocytes potentially inducing the observed impaired activation signature. The predicted interaction between MG SPP1 and NK cells integrin complex <italic>ITGA4-ITGB1</italic> (CD49d-CD29), might mediate NK cell adhesion and migration [<xref ref-type="bibr" rid="c58">58</xref>]. This may facilitate interaction of inhibitory NK receptors KLRB1 and CD94/NKG2A with MG C-type lectin-related ligands and HLA-E, respectively, which could explain the observed impaired activation state of peripheral NK cells. Moreover, SPP1/CD44 interaction in T lymphocytes was described to suppress cell activation and proliferation [<xref ref-type="bibr" rid="c52">52</xref>]. In a comprehensive approach where transcriptional states of human MG were mapped during aging and disease, <italic>SPP1</italic> was found to be differentially expressed in aging-microglia. This was associated to a doubling of the abundance of SPP1<sup>+</sup> GAMs in GBM samples compared to MG from age-matched controls [<xref ref-type="bibr" rid="c59">59</xref>]. These observations support a possible role of MG SPP1 in glioma progression. More recently, myeloid-derived osteopontin (encoded by <italic>SPP1</italic>) was shown to trigger a chronic activation of NFAT2 in tumor-reactive CD8<sup>+</sup> T cells, leading to T cell dysfunction and exhaustion in an experimental mouse model of GBM [<xref ref-type="bibr" rid="c60">60</xref>]. This adds an additional layer of mechanistic evidence for the <italic>SPP1</italic>/Osteopontin-mediated signaling axis leading to CD8<sup>+</sup> T cell dysfunction in GBM.</p>
<p>Limitations of our study include the limited patient number, thereby our study was neither designed nor powered to explore differences in neoplastic cells, given the high inter- and intra-patient variability in glioma cells [<xref ref-type="bibr" rid="c12">12</xref>]. Importantly, our dataset establishes a starting point for further interrogation and provides a first analysis of the transcriptional landscape of the major immune populations in grade 4 glioma within three important regional compartments. Further, we confirmed the observed phenotype of CD8<sup>+</sup> T cells in the blood and tumor periphery by flow cytometry in a cohort of ten additional patients, addressing possible generalization concerns. Together, we provide a regionally resolved map of leukocyte activation in the TME and blood circulation from grade 4 glioma patients, helping the research community to uncover novel therapeutic strategies to combat this fatal disease.</p>
</sec>
<sec id="s4">
<title>Methods</title>
<table-wrap id="utbl1" orientation="portrait" position="float">
<graphic xlink:href="496574v2_utbl1.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="496574v2_utbl1a.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="496574v2_utbl1b.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<sec id="s4a">
<title>Ethics statement</title>
<p>Human adult GBM tissue samples were obtained at the Neurosurgical Clinic of the University Hospital of Basel, Switzerland in accordance with the Swiss Human Research Act and institutional ethics commission (EKNZ 02019-02358). All patients gave written informed consent for tumor biopsy collection and signed a declaration permitting the use of their biopsy specimens in scientific research, including storage in our brain tumor biobank (Req-2019-00553). All patient identifying information was removed and tissue was coded for identification.</p>
</sec>
<sec id="s4b">
<title>Glioma tissue dissociation</title>
<p>Resected glioma tissue samples were immediately placed on ice and transferred to the laboratory for single cell dissociation within 2-3 h after resection. Human brain tissue was manually minced using razor blades and enzymatically dissociated at 37°C for 30 minutes with 1 mg/ml collagenase-4 (#LS004188, Worthington Biochemical Corporation, USA) and 250 U/ml DNAse1 (#10104159001, Roche, Switzerland) in a buffer containing Hank’s Balanced Salt Solution (HBSS) with Ca<sup>2+</sup>/Mg<sup>2+</sup>, 1% MEM non-essential amino acids (Gibco, USA), 1 mM sodium pyruvate (Gibco), 44 mM sodium bi-carbonate (Gibco), 25 mM HEPES (Gibco), 1% GlutaMAX (Gibco) and 1% antibiotic-antimycotic (Sigma-Aldrich, USA). Cells were filtered and separated from dead cells, debris and myelin by a 0.9 M sucrose (#84100, Sigma Aldrich) density gradient centrifugation. Upon ACK-lysis for removal of erythrocytes (#A1049201, Gibco) the now generated single-cell suspension (SCS) was washed, counted and frozen in Bambanker (#BB01, Nippon Genetics, Germany) in liquid nitrogen until use.</p>
</sec>
<sec id="s4c">
<title>PBMCs (Peripheral blood mononuclear cells) preparation</title>
<p>Patient blood samples were directly placed on ice and transferred to the laboratory for PBMC isolation. Blood samples were centrifuged to separate buffy coat from plasma and erythrocytes, followed by standard density gradient centrifugation protocol (#17144002, Ficoll-Paque PLUS, Cytiva, USA) to isolate PBMCs. PBMCs were frozen in Bambanker (#BB01, Nippon Genetics, Germany) in liquid nitrogen until use.</p>
</sec>
<sec id="s4d">
<title>FACS sorting for single cell RNA sequencing (scRNA-seq)</title>
<p>Cryopreserved tumor digests from glioma samples (center and periphery), as well as autologous PBMCs were thawed and washed with excess ice-cold 1xPBS and spun down at 350xg for 5 min. Subsequently, the cells were stained with Live/Dead (APC-Cy7 (Near IR), # L34976, Thermo Fischer) and a cocktail of fluorescently-conjugated antibodies CD11b (FITC, clone M1/70, #101206, BioLegend) and CD45 (FITC, clone 2D1, #368508, BioLegend), and large debris were removed with a 40-μm strainer. All samples were acquired on the BD FACS ARIA Fusion III (Becton Dickinson GmbH, Germany). For single-cell RNA-seq experiments, live and single gated cells were sorted into non-immune cell (CD45<sup>-</sup>CD11b<sup>-</sup>) and immune cell (CD45<sup>+</sup>CD11b<sup>+</sup>) populations. Both populations were directly sorted into Eppendorf tubes with 1xPBS supplemented with 1% BSA for single cell RNA sequencing.</p>
</sec>
<sec id="s4e">
<title>Single cell RNA sequencing (scRNA-seq) – Library preparation and sequencing</title>
<p>Single-cell RNA-seq was performed using Chromium Single Cell 3’ GEM, Library &amp; Gel Bead Kit v3 (#CG000183, 10x Genomics, Pleasanton, CA, USA) following the manufacturer’s protocol. Briefly, non-immune cells and immune cells were mixed at a defined ratio of 1:4. Roughly 8000-10000 cells per sample, diluted at a density of 100–800 cells/μL in PBS plus 1% BSA determined by Cellometer Auto 2000 Cell Viability Counter (Nexelom Bioscience, Lawrence, MA USA), and were loaded onto the chip. The quality and concentration of both cDNA and libraries were assessed using an Agilent BioAnalyzer with High Sensitivity kit (#5067-4626, Agilent, Santa Clara, CA USA) and Qubit Fluorometer with dsDNA HS assay kit (#Q33230, Thermo Fischer Scientific, Waltham, MA USA) according to the manufacturer’s recommendation. For sequencing, samples were mixed in equimolar fashion and sequenced on an Illumina HiSeq 4000 with a targeted read depth of 50,000 reads/cell and sequencing parameters were set for Read1 (28 cycles), Index1 (8 cycles), and Read2 (91 cycles).</p>
</sec>
<sec id="s4f">
<title>Single cell RNA sequencing (scRNA-seq) – Computational analysis</title>
<p>The dataset was analyzed by the Bioinformatics Core Facility, Department of Biomedicine, University of Basel. Read quality was controlled with the FastQC tool (version 0.11.5). Sequencing files were processed using the Salmon Alevin tool (v 1.3.0) [<xref ref-type="bibr" rid="c61">61</xref>] to perform quality control, sample demultiplexing, cell barcode processing, pseudo-alignment of cDNA reads to the human Gencode v35 reference and counting of UMIs. Parameters <italic>--keepCBFraction 1</italic> and <italic>--maxNumBarcodes 100000</italic> were used.</p>
<p>Processing of the UMI counts matrix was performed using the Bioconductor packages DropletUtils (version 1.8.0) [<xref ref-type="bibr" rid="c62">62</xref>, <xref ref-type="bibr" rid="c63">63</xref>], scran (version 1.16.0) [<xref ref-type="bibr" rid="c64">64</xref>, <xref ref-type="bibr" rid="c65">65</xref>] and scater (version 1.16.2) [<xref ref-type="bibr" rid="c66">66</xref>], following mostly the steps illustrated in the OSCA book (<ext-link ext-link-type="uri" xlink:href="http://bioconductor.org/books/release/OSCA/">http://bioconductor.org/books/release/OSCA/</ext-link>) [<xref ref-type="bibr" rid="c65">65</xref>, <xref ref-type="bibr" rid="c67">67</xref>]. Filtering for high-quality cells was done based on library size (at least 2,000 UMI counts per cell), the number of detected genes (at least 700 genes detected) and the percentage of reads mapping to mitochondrial genes (larger than 0% and lower than 15%), based on the distribution observed across cells. Low-abundance genes with average counts per cell lower than 0.006 were filtered out. The presence of doublet cells was investigated with the scDblFinder package (version 1.2.0), and suspicious cells were filtered out (score &gt; 0.6). After quality filtering, the resulting dataset consisted of UMI counts for 15,523 genes and 45,466 cells, ranging from 803 to 9,121 per sample.</p>
<p>UMI counts were normalized with size factors estimated from pools of cells created with the scran package <italic>quickCluster()</italic> function [<xref ref-type="bibr" rid="c64">64</xref>, <xref ref-type="bibr" rid="c68">68</xref>]. To distinguish between genuine biological variability and technical noise we modeled the variance of the log-expression across genes using a Poisson-based mean-variance trend. The scran package <italic>denoisePCA()</italic> function was used to denoise log-expression data by removing principal components corresponding to technical noise. Consistent to the <italic>findElbowPoint()</italic> function from the PCAtools Bioconductor package, this led us to retain the top 5 principal components (PCs), explaining 48.3% of the total variance in the dataset, for the clustering and dimensionality reduction steps.</p>
<p>Since the excluded deeper PCs (PC8 and 10) were associated to patient-specific effects (which in our experimental setup are also confounded with batch effects), this choice dispensed us from performing an additional correction for patient-specific effects. A quantitative test of overlap of cells across patients was made using the CellMixS package [<xref ref-type="bibr" rid="c69">69</xref>] (version 1.12.0) developed to quantify the effectiveness of batch correction methods. We used the cell-specific mixing (CMS) score, which highlighted a very good overlap across cells from different patients in the lymphoid compartment and for the monocytes. The myeloid compartment displayed a slightly elevated patient-specific structure, while it was most pronounced for the CD45 negative subset.</p>
<p>A t-stochastic neighbor embedding (t-SNE) was built with a perplexity of 50 using the top most variable genes (141 genes with estimated biological variance &gt; 0.3, excluding genes with highest proportion of reads in the ambient RNA pool estimated from empty droplets), and the denoised principal components as input. Clustering of cells was performed with hierarchical clustering on the Euclidean distances between cells (with Ward’s criterion to minimize the total variance within each cluster [<xref ref-type="bibr" rid="c70">70</xref>]; package cluster version 2.1.0). The number of clusters used for following analyses was identified by applying a dynamic tree cut (package dynamicTreeCut, version 1.63-1) [<xref ref-type="bibr" rid="c71">71</xref>], resulting in 10 with argument <italic>deepSplit</italic> set to 1, or 22 clusters with argument <italic>deepSplit</italic> set to 2. This clustering was validated with an alternative clustering approach using a graph-based approach and Louvain algorithm for community detection (using the <italic>Find-Neighbors(</italic>) and <italic>FindClusters()</italic> functions from the <italic>Seurat</italic> package [<xref ref-type="bibr" rid="c72">72</xref>] (version 4.3.0), with a resolution of 0.7) which showed a good correspondence to our hierarchical clustering.</p>
<p>The <italic>findMarkers</italic> function of the scran package was used to find the best markers across annotated cell types (parameters <italic>direction=“up”</italic> and <italic>pval.type=“any”</italic>). The top 10 markers for each cell type were extracted and pooled to from a list of 68 markers.</p>
<p>The Bioconductor package <italic>SingleR</italic> (version 1.2.4) was used for cell-type annotation of the cells [<xref ref-type="bibr" rid="c73">73</xref>] using as references (i) a public bulk RNA-seq dataset of sorted immune cell types from human PBMC samples [<xref ref-type="bibr" rid="c16">16</xref>], available through the <italic>celldex</italic> Bioconductor package; (ii) a bulk RNA-seq dataset of sorted immune cell types from the tumor microenvironment of human gliomas [<xref ref-type="bibr" rid="c5">5</xref>] (UMI count matrix and annotation downloaded from <ext-link ext-link-type="uri" xlink:href="https://joycelab.shinyapps.io/braintime/">https://joycelab.shinyapps.io/braintime/</ext-link>); (iii) a 10X genomics scRNA-seq dataset of TAMs from the tumor micro-environment of glioblastoma tumors from 7 newly diagnosed human patients [<xref ref-type="bibr" rid="c9">9</xref>]; (iv) a microglia and a macrophage signature scores were defined by averaging the center and scaled expression levels of gene lists obtained in [<xref ref-type="bibr" rid="c7">7</xref>] and (v) a Smartseq2 scRNA-seq dataset of IDH-wild-type glioblastoma tumors [<xref ref-type="bibr" rid="c17">17</xref>] (downloaded from GEO accession GSE131928). An endothelial score was defined by averaging the center and scaled expression levels of the genes <italic>CDH5</italic>, <italic>VWF</italic>, <italic>CD34</italic> and <italic>PECAM1</italic>.</p>
<p>The SingleR high-quality assignments (pruned scores) from the comparisons to the multiple references (some being better at enlightening some immune subsets than others) were used to manually derive a consensus cell type annotation for each cluster. This manual annotation was done jointly with the input from the signature scores and relative expression patterns of known marker genes and of cluster-specific genes.</p>
<p>When we judged that the resolution was not sufficient to discriminate well the subtypes of cells within a subset (in particular for the CD45neg and myeloid cells subsets), we isolated these cells and re-performed selection of hyper-variable genes, dimensionality reduction and clustering on the isolated subset.</p>
<p>Differential abundance analysis of the identified cell types between tumor sites was performed using <italic>limma-voom</italic> [<xref ref-type="bibr" rid="c74">74</xref>]. This method, implemented in the <italic>diffcyt</italic> package, was shown to be able to handle well the overdispersion in the cell type proportions estimates typically observed with single cell technologies [<xref ref-type="bibr" rid="c75">75</xref>]. Differential abundance of cell types was considered to be significant at a false discovery rate (FDR) lower than 5 %. To provide increased resolution into local trends within the tumor innate immune subset we used the <italic>miloR</italic> bioconductor package [<xref ref-type="bibr" rid="c76">76</xref>] (version 1.4.0) to test for differential abundance on neighborhoods of a <italic>k</italic>-nearest neighbor graph. Testing was done with <italic>limma-voom</italic> similarly to above. Cell type labels were assigned to each neighborhood by finding the most abundant cell type across cells and requiring that at least 70% of the cells come from one cell type.</p>
<p>Differential expression between tumor sites, or between PBMC cells and tumor periphery cells, stratified by annotated cell type, was performed using a pseudo-bulk approach, which was shown to be the best-performing approach for differential expression testing in recent benchmarks [<xref ref-type="bibr" rid="c77">77</xref>]. UMI counts were summed across cells from each cell type in each sample when at least 20 cells could be aggregated. The aggregated samples were then treated as bulk RNA-seq samples [<xref ref-type="bibr" rid="c78">78</xref>] and for each pairwise comparison genes were filtered to keep genes detected in at least 5% of the cells aggregated. The package edgeR (version 3.30.3) [<xref ref-type="bibr" rid="c79">79</xref>] was used to perform TMM normalization [<xref ref-type="bibr" rid="c80">80</xref>] and to test for differential expression with the Generalized Linear Model (GLM) framework, using a model accounting for patient-specific effects. Genes with a FDR lower than 5 % were considered differentially expressed. To validate our differential expression analysis, we rerun a pseudo-bulk expression analysis using DESeq2 (version 1.38.3) [<xref ref-type="bibr" rid="c81">81</xref>] for the main immune populations in the periphery versus center and periphery versus PBMC comparison. Although, the results were not identical, they overall agreed with edgeR (Supplementary File 7). Gene set enrichment analysis was performed with the function camera [<xref ref-type="bibr" rid="c82">82</xref>] on gene sets from the Molecular Signature Database (MSigDB, version 7.4) [<xref ref-type="bibr" rid="c27">27</xref>, <xref ref-type="bibr" rid="c83">83</xref>]. We retained only sets containing more than 5 genes, and gene sets with a FDR lower than 5% were considered as significant.</p>
</sec>
<sec id="s4g">
<title>Cell chat analysis</title>
<p>The R package CellChat (1.1.3) [<xref ref-type="bibr" rid="c50">50</xref>] was used to analyze cell-cell interactions in our dataset (with previously annotated 9 cell types). We followed the recommended workflow to infer the cell state-specific communications (using <italic>identifyOverExpressedGenes</italic>, <italic>identifyOver-ExpressedInteractions</italic> and <italic>projectData</italic> with the default parameters). We performed 3 separate analyses, on the center and the periphery subsets and a comparison analysis as described in the official workflow. We visualized the significant interactions for the microglia cluster using <italic>netVisual_chord_gene</italic> and used <italic>plotGeneExpression</italic> to display of the expression of all genes involved SPP1 signaling pathway in the cell populations. Finally, <italic>netAnalysis_signalin-gRole_scatter</italic> was used to calculate and visualize incoming and outgoing signaling strength.</p>
</sec>
<sec id="s4h">
<title>Flow cytometry analysis of paired PBMC and periphery samples</title>
<p>Cryopreserved samples were thawed and washed with excess ice-cold 1xPBS and spun down at 350xg for 5 min. Cells were resuspended in FACS buffer (PBS plus 2% FBS) and blocked with monoclonal antibody to CD16/32 (Human TruStain FcX, #422302, Biolegend) for 10 min at 4°C before staining with surface antibodies: CD45RA (PE, clone HI100, #304108), CD45RO (APC, clone UCHL1, #304210), CD3e (BV650, clone UCHT1, #300468), CD8a (BV421, clone RPA-T8, #301036), CCR7 (FITC, clone G043H7, #353216), CD62L (AF700, clone DREG-56, #304820), CD69 (APC-Cy7, clone FN50, #310914), CD103 (PerCP/Cy5.5, clone Ber-ACT8, #350226) and CX3CR1 (PE/Cy7, clone 2A9-1, #341612). All antibodies were purchased from BioLegend, USA. Cells were stained for 30 min at 4°C, and subsequently washed with FACS buffer. To exclude dead cells Zombie Aqua Fixable Viability Kit (#423102, 1:100, BioLegend) was added. Acquisition was performed on a CytoFLEX (Beckman). Data was analyzed using FlowJo software, version 10.8.1 (TreeStar). Gates were drawn by using Fluorescent Minus One (FMO) controls.</p>
</sec>
<sec id="s4i">
<title>Statistical analysis of flow cytometry data</title>
<p>Data analysis and graph generation was performed using GraphPad Prism 9 (GraphPad Prism Software Inc.). Paired comparisons between two groups were performed using Wilcoxon matched-pairs signed rank test. Differences of more than two paired groups were assessed using repeated measures one-way ANOVA test, followed by post-hoc Šidák’s multiple comparisons correction. A <italic>p</italic> value &lt; 0.05 was considered statistically significant. *<italic>p</italic> ≤ 0.05, **<italic>p</italic> ≤ 0.01, ***<italic>p</italic> ≤ 0.001, ****<italic>p</italic> ≤ 0.0001.</p>
</sec>
<sec id="s4j">
<title>Graphical illustrations</title>
<p>All graphical illustrations were created with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender.com</ext-link>.</p>
</sec>
</sec>
<sec id="d1e1989" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material id="d1e2092">
<label>Supplement Figures</label>
<media xlink:href="supplements/496574_file02.pdf"/>
</supplementary-material>
</sec>
</body>
<back>
<sec id="s5">
<title>Data availability</title>
<p>The UMI count matrix and cell metadata from the scRNA-seq dataset are available on GEO under accession number <underline>GSE197543</underline>. The remaining data are available within the Article and Supplementary Information.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Stupp</surname>, <given-names>R.</given-names></string-name>, <string-name><given-names>W.P.</given-names> <surname>Mason</surname></string-name>, <string-name><given-names>M.J.</given-names> <surname>van den Bent</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Weller</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Fisher</surname></string-name>, <string-name><given-names>M.J.</given-names> <surname>Taphoorn</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Belanger</surname></string-name>, <string-name><given-names>A.A.</given-names> <surname>Brandes</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Marosi</surname></string-name>, <string-name><given-names>U.</given-names> <surname>Bogdahn</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Curschmann</surname></string-name>, <string-name><given-names>R.C.</given-names> <surname>Janzer</surname></string-name>, <string-name><given-names>S.K.</given-names> <surname>Ludwin</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Gorlia</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Allgeier</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Lacombe</surname></string-name>, <string-name><given-names>J.G.</given-names> <surname>Cairncross</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Eisenhauer</surname></string-name>, and <string-name><given-names>R.O.</given-names> <surname>Mirimanoff</surname></string-name>, <article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title>. <source>N Engl J Med</source>, <year>2005</year>. <volume>352</volume>(<issue>10</issue>): p. <fpage>987</fpage>–<lpage>96</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Bowman</surname>, <given-names>R.L.</given-names></string-name>, <string-name><given-names>F.</given-names> <surname>Klemm</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Akkari</surname></string-name>, <string-name><given-names>S.M.</given-names> <surname>Pyonteck</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Sevenich</surname></string-name>, <string-name><given-names>D.F.</given-names> <surname>Quail</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Dhara</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Simpson</surname></string-name>, <string-name><given-names>E.E.</given-names> <surname>Gardner</surname></string-name>, <string-name><given-names>C.A.</given-names> <surname>Iacobuzio-Donahue</surname></string-name>, <string-name><given-names>C.W.</given-names> <surname>Brennan</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Tabar</surname></string-name>, <string-name><given-names>P.H.</given-names> <surname>Gutin</surname></string-name>, and <string-name><given-names>J.A.</given-names> <surname>Joyce</surname></string-name>, <article-title>Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies</article-title>. <source>Cell Rep</source>, <year>2016</year>. <volume>17</volume>(<issue>9</issue>): p. <fpage>2445</fpage>–<lpage>2459</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Reardon</surname>, <given-names>D.A.</given-names></string-name>, <string-name><given-names>T.J.</given-names> <surname>Kaley</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Dietrich</surname></string-name>, <string-name><given-names>J.L.</given-names> <surname>Clarke</surname></string-name>, <string-name><given-names>G.P.</given-names> <surname>Dunn</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Lim</surname></string-name>, <string-name><given-names>T.F.</given-names> <surname>Cloughesy</surname></string-name>, <string-name><given-names>H.K.</given-names> <surname>Gan</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>Park</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Schwarzenberger</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Ricciardi</surname></string-name>, <string-name><given-names>M.J.</given-names> <surname>Macri</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Ryan</surname></string-name>, and <string-name><given-names>R.R.</given-names> <surname>Venhaus</surname></string-name>, <article-title>Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update</article-title>. <source>Journal of Clinical Oncology</source>, <year>2017</year>. <volume>35</volume>(15_suppl): p. 2042-2042.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Reardon</surname>, <given-names>D.A.</given-names></string-name>, <string-name><given-names>A.</given-names> <surname>Omuro</surname></string-name>, <string-name><given-names>A.A.</given-names> <surname>Brandes</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Rieger</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Wick</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Sepulveda</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Phuphanich</surname></string-name>, <string-name><given-names>P.</given-names> <surname>de Souza</surname></string-name>, <string-name><given-names>M.S.</given-names> <surname>Ahluwalia</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Lim</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Vlahovic</surname></string-name>, and <string-name><given-names>J.</given-names> <surname>Sampson</surname></string-name>, <article-title>OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143</article-title>. <source>NeuroOncology</source>, <year>2017</year>. <volume>19</volume>(<issue>Suppl 3</issue>): p. iii21-iii21.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Klemm</surname>, <given-names>F.</given-names></string-name>, <string-name><given-names>R.R.</given-names> <surname>Maas</surname></string-name>, <string-name><given-names>R.L.</given-names> <surname>Bowman</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Kornete</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Soukup</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Nassiri</surname></string-name>, <string-name><given-names>J.P.</given-names> <surname>Brouland</surname></string-name>, <string-name><given-names>C.A.</given-names> <surname>Iacobuzio-Donahue</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Brennan</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Tabar</surname></string-name>, <string-name><given-names>P.H.</given-names> <surname>Gutin</surname></string-name>, <string-name><given-names>R.T.</given-names> <surname>Daniel</surname></string-name>, <string-name><given-names>M.E.</given-names> <surname>Hegi</surname></string-name>, and <string-name><given-names>J.A.</given-names> <surname>Joyce</surname></string-name>, <article-title>Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells</article-title>. <source>Cell</source>, <year>2020</year>. <volume>181</volume>(<issue>7</issue>): p. <fpage>1643</fpage>–<lpage>1660</lpage>.e17.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Friebel</surname>, <given-names>E.</given-names></string-name>, <string-name><given-names>K.</given-names> <surname>Kapolou</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Unger</surname></string-name>, <string-name><given-names>N.G.</given-names> <surname>Núñez</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Utz</surname></string-name>, <string-name><given-names>E.J.</given-names> <surname>Rushing</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Regli</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Weller</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Greter</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Tugues</surname></string-name>, <string-name><given-names>M.C.</given-names> <surname>Neidert</surname></string-name>, and <string-name><given-names>B.</given-names> <surname>Becher</surname></string-name>, <article-title>Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes</article-title>. <source>Cell</source>, <year>2020</year>. <volume>181</volume>(<issue>7</issue>): p. <fpage>1626</fpage>–<lpage>1642</lpage>.e20.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Müller</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>G.</given-names> <surname>Kohanbash</surname></string-name>, <string-name><given-names>S.J.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Alvarado</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Carrera</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Bhaduri</surname></string-name>, <string-name><given-names>P.B.</given-names> <surname>Watchmaker</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Yagnik</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Di Lullo</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Malatesta</surname></string-name>, <string-name><given-names>N.M.</given-names> <surname>Amankulor</surname></string-name>, <string-name><given-names>A.R.</given-names> <surname>Kriegstein</surname></string-name>, <string-name><given-names>D.A.</given-names> <surname>Lim</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Aghi</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Okada</surname></string-name>, and <string-name><given-names>A.</given-names> <surname>Diaz</surname></string-name>, <article-title>Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment</article-title>. <source>Genome Biology</source>, <year>2017</year>. <volume>18</volume>(<issue>1</issue>): p. <fpage>234</fpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Abdelfattah</surname>, <given-names>N.</given-names></string-name>, <string-name><given-names>P.</given-names> <surname>Kumar</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>J.-S.</given-names> <surname>Leu</surname></string-name>, <string-name><given-names>W.F.</given-names> <surname>Flynn</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Gao</surname></string-name>, <string-name><given-names>D.S.</given-names> <surname>Baskin</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Pichumani</surname></string-name>, <string-name><given-names>O.B.</given-names> <surname>Ijare</surname></string-name>, <string-name><given-names>S.L.</given-names> <surname>Wood</surname></string-name>, <string-name><given-names>S.Z.</given-names> <surname>Powell</surname></string-name>, <string-name><given-names>D.L.</given-names> <surname>Haviland</surname></string-name>, <string-name><given-names>B.C.</given-names> <surname>Parker Kerrigan</surname></string-name>, <string-name><given-names>F.F.</given-names> <surname>Lang</surname></string-name>, <string-name><given-names>S.S.</given-names> <surname>Prabhu</surname></string-name>, <string-name><given-names>K.M.</given-names> <surname>Huntoon</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>B.Y.S.</given-names> <surname>Kim</surname></string-name>, <string-name><given-names>J.</given-names> <surname>George</surname></string-name>, and <string-name><given-names>K.</given-names> <surname>Yun</surname></string-name>, <article-title>Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target</article-title>. <source>Nature Communications</source>, <year>2022</year>. <volume>13</volume>(<issue>1</issue>): p. <fpage>767</fpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Pombo Antunes</surname>, <given-names>A.R.</given-names></string-name>, <string-name><given-names>I.</given-names> <surname>Scheyltjens</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Lodi</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Messiaen</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Antoranz</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Duerinck</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Kancheva</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Martens</surname></string-name>, <string-name><given-names>K.</given-names> <surname>De Vlaminck</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Van Hove</surname></string-name>, <string-name><given-names>S.S.</given-names> <surname>Kjølner Hansen</surname></string-name>, <string-name><given-names>F.M.</given-names> <surname>Bosisio</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Van der Borght</surname></string-name>, <string-name><given-names>S.</given-names> <surname>De Vleeschouwer</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Sciot</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Bouwens</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Verfaillie</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Vandamme</surname></string-name>, <string-name><given-names>R.E.</given-names> <surname>Vandenbroucke</surname></string-name>, <string-name><given-names>O.</given-names> <surname>De Wever</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Saeys</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Guilliams</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Gysemans</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Neyns</surname></string-name>, <string-name><given-names>F.</given-names> <surname>De Smet</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Lambrechts</surname></string-name>, <string-name><given-names>J.A.</given-names> <surname>Van Ginderachter</surname></string-name>, and <string-name><given-names>K.</given-names> <surname>Movahedi</surname></string-name>, <article-title>Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization</article-title>. <source>Nature Neuroscience</source>, <year>2021</year>. <volume>24</volume>(<issue>4</issue>): p. <fpage>595</fpage>–<lpage>610</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Goswami</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>T.</given-names> <surname>Walle</surname></string-name>, <string-name><given-names>A.E.</given-names> <surname>Cornish</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Basu</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Anandhan</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Fernandez</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Vence</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Blando</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>S.S.</given-names> <surname>Yadav</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Ott</surname></string-name>, <string-name><given-names>L.Y.</given-names> <surname>Kong</surname></string-name>, <string-name><given-names>A.B.</given-names> <surname>Heimberger</surname></string-name>, <string-name><given-names>J.</given-names> <surname>de Groot</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Sepesi</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Overman</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Kopetz</surname></string-name>, <string-name><given-names>J.P.</given-names> <surname>Allison</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Pe’er</surname></string-name>, and <string-name><given-names>P.</given-names> <surname>Sharma</surname></string-name>, <article-title>Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma</article-title>. <source>Nature Medicine</source>, <year>2020</year>. <volume>26</volume>(<issue>1</issue>): p. <fpage>39</fpage>–<lpage>46</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>, <given-names>A.X.</given-names></string-name>, <string-name><given-names>R.D.</given-names> <surname>Gartrell</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>P.S.</given-names> <surname>Upadhyayula</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Yuan</surname></string-name>, <string-name><given-names>H.E.</given-names> <surname>Minns</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Dovas</surname></string-name>, <string-name><given-names>J.N.</given-names> <surname>Bruce</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Lasorella</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Iavarone</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Canoll</surname></string-name>, <string-name><given-names>P.A.</given-names> <surname>Sims</surname></string-name>, and <string-name><given-names>R.</given-names> <surname>Rabadan</surname></string-name>, <article-title>Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker</article-title>. <source>Genome Medicine</source>, <year>2021</year>. <volume>13</volume>(<issue>1</issue>): p. <fpage>88</fpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Darmanis</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>S.A.</given-names> <surname>Sloan</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Croote</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Mignardi</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Chernikova</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Samghababi</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Neff</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Kowarsky</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Caneda</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>S.D.</given-names> <surname>Chang</surname></string-name>, <string-name><given-names>I.D.</given-names> <surname>Connolly</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>B. A.</given-names> <surname>Barres</surname></string-name>, <string-name><given-names>M.H.</given-names> <surname>Gephart</surname></string-name>, and <string-name><given-names>S.R.</given-names> <surname>Quake</surname></string-name>, <article-title>Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma</article-title>. <source>Cell Rep</source>, <year>2017</year>. <volume>21</volume>(<issue>5</issue>): p. <fpage>1399</fpage>–<lpage>1410</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Landry</surname>, <given-names>A.P.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Balas</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Alli</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Spears</surname></string-name>, and <string-name><given-names>Z.</given-names> <surname>Zador</surname></string-name>, <article-title>Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma</article-title>. <source>Scientific Reports</source>, <year>2020</year>. <volume>10</volume>(<issue>1</issue>): p. <fpage>19542</fpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Louis</surname>, <given-names>D.N.</given-names></string-name>, <string-name><given-names>A.</given-names> <surname>Perry</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Wesseling</surname></string-name>, <string-name><given-names>D.J.</given-names> <surname>Brat</surname></string-name>, <string-name><given-names>I.A.</given-names> <surname>Cree</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Figarella-Branger</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Hawkins</surname></string-name>, <string-name><given-names>H.K.</given-names> <surname>Ng</surname></string-name>, <string-name><given-names>S.M.</given-names> <surname>Pfister</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Reifenberger</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Soffietti</surname></string-name>, <string-name><given-names>A.</given-names> <surname>von Deimling</surname></string-name>, and <string-name><given-names>D.W.</given-names> <surname>Ellison</surname></string-name>, <article-title>The 2021 WHO Classification of Tumors of the Central Nervous System: a summary</article-title>. <source>Neuro-Oncology</source>, <year>2021</year>. <volume>23</volume>(<issue>8</issue>): p. <fpage>1231</fpage>–<lpage>1251</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Linderman</surname>, <given-names>G.C.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Rachh</surname></string-name>, <string-name><given-names>J.G.</given-names> <surname>Hoskins</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Steinerberger</surname></string-name>, and <string-name><given-names>Y.</given-names> <surname>Kluger</surname></string-name>, <article-title>Fast interpolation-based t-SNE for improved visualization of single-cell RNA-seq data</article-title>. <source>Nat Methods</source>, <year>2019</year>. <volume>16</volume>(<issue>3</issue>): p. <fpage>243</fpage>–<lpage>245</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Monaco</surname>, <given-names>G.</given-names></string-name>, <string-name><given-names>B.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Mustafah</surname></string-name>, <string-name><given-names>Y.Y.</given-names> <surname>Hwang</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Carré</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Burdin</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Visan</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Ceccarelli</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Poidinger</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Zippelius</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Pedro de Magalhães</surname></string-name>, and <string-name><given-names>A.</given-names> <surname>Larbi</surname></string-name>, <article-title>RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types</article-title>. <source>Cell Rep</source>, <year>2019</year>. <volume>26</volume>(<issue>6</issue>): p. <fpage>1627</fpage>–<lpage>1640</lpage>.e7.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Neftel</surname>, <given-names>C.</given-names></string-name>, <string-name><given-names>J.</given-names> <surname>Laffy</surname></string-name>, <string-name><given-names>M.G.</given-names> <surname>Filbin</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Hara</surname></string-name>, <string-name><given-names>M.E.</given-names> <surname>Shore</surname></string-name>, <string-name><given-names>G.J.</given-names> <surname>Rahme</surname></string-name>, <string-name><given-names>A.R.</given-names> <surname>Richman</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Silverbush</surname></string-name>, <string-name><given-names>M.L.</given-names> <surname>Shaw</surname></string-name>, <string-name><given-names>C.M.</given-names> <surname>Hebert</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Dewitt</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Gritsch</surname></string-name>, <string-name><given-names>E.M.</given-names> <surname>Perez</surname></string-name>, <string-name><given-names>L.N.</given-names> <surname>Gonzalez Castro</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Lan</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Druck</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Rodman</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Dionne</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Kaplan</surname></string-name>, <string-name><given-names>M.S.</given-names> <surname>Bertalan</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Small</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Pelton</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Becker</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Bonal</surname></string-name>, <string-name><given-names>Q.-D.</given-names> <surname>Nguyen</surname></string-name>, <string-name><given-names>R.L.</given-names> <surname>Servis</surname></string-name>, <string-name><given-names>J.M.</given-names> <surname>Fung</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Mylvaganam</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Mayr</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Gojo</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Haberler</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Geyeregger</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Czech</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Slavc</surname></string-name>, <string-name><given-names>B.V.</given-names> <surname>Nahed</surname></string-name>, <string-name><given-names>W.T.</given-names> <surname>Curry</surname></string-name>, <string-name><given-names>B.S.</given-names> <surname>Carter</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Wakimoto</surname></string-name>, <string-name><given-names>P.K.</given-names> <surname>Brastianos</surname></string-name>, <string-name><given-names>T.T.</given-names> <surname>Batchelor</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Stemmer-Rachamimov</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Martinez-Lage</surname></string-name>, <string-name><given-names>M.P.</given-names> <surname>Frosch</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Stamenkovic</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Riggi</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Rheinbay</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Monje</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Rozenblatt-Rosen</surname></string-name>, <string-name><given-names>D.P.</given-names> <surname>Cahill</surname></string-name>, <string-name><given-names>A.P.</given-names> <surname>Patel</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Hunter</surname></string-name>, <string-name><given-names>I.M.</given-names> <surname>Verma</surname></string-name>, <string-name><given-names>K.L.</given-names> <surname>Ligon</surname></string-name>, <string-name><given-names>D.N.</given-names> <surname>Louis</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Regev</surname></string-name>, <string-name><given-names>B.E.</given-names> <surname>Bernstein</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Tirosh</surname></string-name>, and <string-name><given-names>M.L.</given-names> <surname>Suvà</surname></string-name>, <article-title>An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma</article-title>. <source>Cell</source>, <year>2019</year>. <volume>178</volume>(<issue>4</issue>): p. <fpage>835</fpage>–<lpage>849</lpage>.e21.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Pinton</surname>, <given-names>L.</given-names></string-name>, <string-name><given-names>E.</given-names> <surname>Masetto</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Vettore</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Solito</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Magri</surname></string-name>, <string-name><given-names>M.</given-names> <surname>D’Andolfi</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Del Bianco</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Lollo</surname></string-name>, <string-name><given-names>J.P.</given-names> <surname>Benoit</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Okada</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Diaz</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Della Puppa</surname></string-name>, and <string-name><given-names>S.</given-names> <surname>Mandruzzato</surname></string-name>, <article-title>The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion</article-title>. <source>J Immunother Cancer</source>, <year>2019</year>. <volume>7</volume>(<issue>1</issue>): p. <fpage>58</fpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Nguyen</surname>, <given-names>A.T.</given-names></string-name>, <string-name><given-names>K.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Hu</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Miao</surname></string-name>, <string-name><given-names>J.A.</given-names> <surname>Azevedo</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Suh</surname></string-name>, <string-name><given-names>V.M.</given-names> <surname>Van Deerlin</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Choi</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Roeder</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Li</surname></string-name>, and <string-name><given-names>E.B.</given-names> <surname>Lee</surname></string-name>, <article-title>APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer’s disease</article-title>. <source>Acta Neuropathol</source>, <year>2020</year>. <volume>140</volume>(<issue>4</issue>): p. <fpage>477</fpage>–<lpage>493</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Soroceanu</surname>, <given-names>L.</given-names></string-name>, <string-name><given-names>R.</given-names> <surname>Murase</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Limbad</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Singer</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Allison</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Adrados</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Kawamura</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Pakdel</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Fukuyo</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Nguyen</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Khan</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Arauz</surname></string-name>, <string-name><given-names>G.L.</given-names> <surname>Yount</surname></string-name>, <string-name><given-names>D.H.</given-names> <surname>Moore</surname></string-name>, <string-name><given-names>P.Y.</given-names> <surname>Desprez</surname></string-name>, and <string-name><given-names>S.D.</given-names> <surname>McAllister</surname></string-name>, <article-title>Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target</article-title>. <source>Cancer Res</source>, <year>2013</year>. <volume>73</volume>(<issue>5</issue>): p. <fpage>1559</fpage>–<lpage>69</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Papaspyridonos</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>I.</given-names> <surname>Matei</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Huang</surname></string-name>, <string-name><given-names>M.</given-names> <surname>do Rosario Andre</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Brazier-Mitouart</surname></string-name>, <string-name><given-names>J.C.</given-names> <surname>Waite</surname></string-name>, <string-name><given-names>A.S.</given-names> <surname>Chan</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Kalter</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Ramos</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Williams</surname></string-name>, <string-name><given-names>J.D.</given-names> <surname>Wolchok</surname></string-name>, <string-name><given-names>P.B.</given-names> <surname>Chapman</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Peinado</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Anandasabapathy</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>Ocean</surname></string-name>, <string-name><given-names>R.N.</given-names> <surname>Kaplan</surname></string-name>, <string-name><given-names>J.P.</given-names> <surname>Greenfield</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Bromberg</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Skokos</surname></string-name>, and <string-name><given-names>D.</given-names> <surname>Lyden</surname></string-name>, <article-title>Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation</article-title>. <source>Nature Communications</source>, <year>2015</year>. <volume>6</volume>(<issue>1</issue>): p. <fpage>6840</fpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Holtman</surname>, <given-names>I.R.</given-names></string-name>, <string-name><given-names>D.</given-names> <surname>Skola</surname></string-name>, and <string-name><given-names>C.K.</given-names> <surname>Glass</surname></string-name>, <article-title>Transcriptional control of microglia phenotypes in health and disease</article-title>. <source>The Journal of Clinical Investigation</source>, <year>2017</year>. <volume>127</volume>(<issue>9</issue>): p. <fpage>3220</fpage>–<lpage>3229</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Nomaru</surname>, <given-names>H.</given-names></string-name>, <string-name><given-names>K.</given-names> <surname>Sakumi</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Katogi</surname></string-name>, <string-name><given-names>Y.N.</given-names> <surname>Ohnishi</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Kajitani</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Tsuchimoto</surname></string-name>, <string-name><given-names>E.J.</given-names> <surname>Nestler</surname></string-name>, and <string-name><given-names>Y.</given-names> <surname>Nakabeppu</surname></string-name>, <article-title>Fosb gene products contribute to excitotoxic microglial activation by regulating the expression of complement C5a receptors in microglia</article-title>. <source>Glia</source>, <year>2014</year>. <volume>62</volume>(<issue>8</issue>): p. <fpage>1284</fpage>–<lpage>98</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Sweet</surname>, <given-names>D.R.</given-names></string-name>, <string-name><given-names>N.T.</given-names> <surname>Vasudevan</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Fan</surname></string-name>, <string-name><given-names>C.E.</given-names> <surname>Booth</surname></string-name>, <string-name><given-names>K.S.</given-names> <surname>Keerthy</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Liao</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Vinayachandran</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Takami</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Tugal</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Sharma</surname></string-name>, <string-name><given-names>E.R.</given-names> <surname>Chan</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Qing</surname></string-name>, <string-name><given-names>S.L.</given-names> <surname>Gerson</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Fu</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Wynshaw-Boris</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Sangwung</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Nayak</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Holvoet</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Matoba</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Lu</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Zhou</surname></string-name>, and <string-name><given-names>M.K.</given-names> <surname>Jain</surname></string-name>, <article-title>Myeloid Krüppel-like factor 2 is a critical regulator of metabolic inflammation</article-title>. <source>Nature Communications</source>, <year>2020</year>. <volume>11</volume>(<issue>1</issue>): p. <fpage>5872</fpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Salojin</surname>, <given-names>K.V.</given-names></string-name>, <string-name><given-names>I.B.</given-names> <surname>Owusu</surname></string-name>, <string-name><given-names>K.A.</given-names> <surname>Millerchip</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Potter</surname></string-name>, <string-name><given-names>K.A.</given-names> <surname>Platt</surname></string-name>, and <string-name><given-names>T.</given-names> <surname>Oravecz</surname></string-name>, <article-title>Essential role of MAPK phosphatase-1 in the negative control of innate immune responses</article-title>. <source>J Immunol</source>, <year>2006</year>. <volume>176</volume>(<issue>3</issue>): p. <fpage>1899</fpage>–<lpage>907</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Lee</surname>, <given-names>H.</given-names></string-name>, <string-name><given-names>S.</given-names> <surname>Cha</surname></string-name>, <string-name><given-names>M.S.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>G.J.</given-names> <surname>Cho</surname></string-name>, <string-name><given-names>W.S.</given-names> <surname>Choi</surname></string-name>, and <string-name><given-names>K.</given-names> <surname>Suk</surname></string-name>, <article-title>Role of antiproliferative B cell translocation gene-1 as an apoptotic sensitizer in activation-induced cell death of brain microglia</article-title>. <source>J Immunol</source>, <year>2003</year>. <volume>171</volume>(<issue>11</issue>): p. <fpage>5802</fpage>–<lpage>11</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Liberzon</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>C.</given-names> <surname>Birger</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Thorvaldsdóttir</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Ghandi</surname></string-name>, <string-name><given-names>J.P.</given-names> <surname>Mesirov</surname></string-name>, and <string-name><given-names>P.</given-names> <surname>Tamayo</surname></string-name>, <article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title>. <source>Cell systems</source>, <year>2015</year>. <volume>1</volume>(<issue>6</issue>): p. <fpage>417</fpage>–<lpage>425</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Walker</surname>, <given-names>D.G.</given-names></string-name> and <string-name><given-names>L.F.</given-names> <surname>Lue</surname></string-name>, <article-title>Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains</article-title>. <source>Alzheimers Res Ther</source>, <year>2015</year>. <volume>7</volume>(<issue>1</issue>): p. <fpage>56</fpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Hopperton</surname>, <given-names>K.E.</given-names></string-name>, <string-name><given-names>D.</given-names> <surname>Mohammad</surname></string-name>, <string-name><given-names>M.O.</given-names> <surname>Trépanier</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Giuliano</surname></string-name>, and <string-name><given-names>R.P.</given-names> <surname>Bazinet</surname></string-name>, <article-title>Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review</article-title>. <source>Molecular Psychiatry</source>, <year>2018</year>. <volume>23</volume>(<issue>2</issue>): p. <fpage>177</fpage>–<lpage>198</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Hammond</surname>, <given-names>T.R.</given-names></string-name>, <string-name><given-names>C.</given-names> <surname>Dufort</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Dissing-Olesen</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Giera</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Young</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Wysoker</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>Walker</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Gergits</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Segel</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Nemesh</surname></string-name>, <string-name><given-names>S.E.</given-names> <surname>Marsh</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Saunders</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Macosko</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Ginhoux</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>R.J.M.</given-names> <surname>Franklin</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Piao</surname></string-name>, <string-name><given-names>S.A.</given-names> <surname>McCarroll</surname></string-name>, and <string-name><given-names>B.</given-names> <surname>Stevens</surname></string-name>, <article-title>Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes</article-title>. <source>Immunity</source>, <year>2019</year>. <volume>50</volume>(<issue>1</issue>): p. <fpage>253</fpage>–<lpage>271</lpage>.e6.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>McQuade</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>Y.J.</given-names> <surname>Kang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Hasselmann</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Jairaman</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Sotelo</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Coburn</surname></string-name>, <string-name><given-names>S.K.</given-names> <surname>Shabestari</surname></string-name>, <string-name><given-names>J.P.</given-names> <surname>Chadarevian</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Fote</surname></string-name>, <string-name><given-names>C.H.</given-names> <surname>Tu</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Danhash</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Silva</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Martinez</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Cotman</surname></string-name>, <string-name><given-names>G.A.</given-names> <surname>Prieto</surname></string-name>, <string-name><given-names>L.M.</given-names> <surname>Thompson</surname></string-name>, <string-name><given-names>J.S.</given-names> <surname>Steffan</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Smith</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Davtyan</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Cahalan</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Cho</surname></string-name>, and <string-name><given-names>M.</given-names> <surname>Blurton-Jones</surname></string-name>, <article-title>Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer’s disease</article-title>. <source>Nature Communications</source>, <year>2020</year>. <volume>11</volume>(<issue>1</issue>): p. <fpage>5370</fpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Rothe</surname>, <given-names>T.</given-names></string-name>, <string-name><given-names>N.</given-names> <surname>Ipseiz</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Faas</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Lang</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Perez-Branguli</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Metzger</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Ichinose</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Winner</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Schett</surname></string-name>, and <string-name><given-names>G.</given-names> <surname>Krönke</surname></string-name>, <article-title>The Nuclear Receptor Nr4a1 Acts as a Microglia Rheostat and Serves as a Therapeutic Target in Autoimmune-Driven Central Nervous System Inflammation</article-title>. <source>Journal of immunology (Baltimore, Md. : 1950)</source>, <year>2017</year>. <volume>198</volume>(<issue>10</issue>): p. <fpage>3878</fpage>–<lpage>3885</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Saijo</surname>, <given-names>K.</given-names></string-name>, <string-name><given-names>B.</given-names> <surname>Winner</surname></string-name>, <string-name><given-names>C.T.</given-names> <surname>Carson</surname></string-name>, <string-name><given-names>J.G.</given-names> <surname>Collier</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Boyer</surname></string-name>, <string-name><given-names>M.G.</given-names> <surname>Rosenfeld</surname></string-name>, <string-name><given-names>F.H.</given-names> <surname>Gage</surname></string-name>, and <string-name><given-names>C.K.</given-names> <surname>Glass</surname></string-name>, <article-title>A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death</article-title>. <source>Cell</source>, <year>2009</year>. <volume>137</volume>(<issue>1</issue>): p. <fpage>47</fpage>–<lpage>59</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Szabo</surname>, <given-names>P.A.</given-names></string-name>, <string-name><given-names>H.M.</given-names> <surname>Levitin</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Miron</surname></string-name>, <string-name><given-names>M.E.</given-names> <surname>Snyder</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Senda</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Yuan</surname></string-name>, <string-name><given-names>Y.L.</given-names> <surname>Cheng</surname></string-name>, <string-name><given-names>E.C.</given-names> <surname>Bush</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Dogra</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Thapa</surname></string-name>, <string-name><given-names>D.L.</given-names> <surname>Farber</surname></string-name>, and <string-name><given-names>P.A.</given-names> <surname>Sims</surname></string-name>, <article-title>Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease</article-title>. <source>Nature Communications</source>, <year>2019</year>. <volume>10</volume>(<issue>1</issue>): p. <fpage>4706</fpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Alegre</surname>, <given-names>M.L.</given-names></string-name>, <string-name><given-names>P.J.</given-names> <surname>Noel</surname></string-name>, <string-name><given-names>B.J.</given-names> <surname>Eisfelder</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Chuang</surname></string-name>, <string-name><given-names>M.R.</given-names> <surname>Clark</surname></string-name>, <string-name><given-names>S.L.</given-names> <surname>Reiner</surname></string-name>, and <string-name><given-names>C.B.</given-names> <surname>Thompson</surname></string-name>, <article-title>Regulation of surface and intracellular expression of CTLA4 on mouse T cells</article-title>. <source>J Immunol</source>, <year>1996</year>. <volume>157</volume>(<issue>11</issue>): p. <fpage>4762</fpage>–<lpage>70</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Johnson</surname>, <given-names>D.B.</given-names></string-name>, <string-name><given-names>M.J.</given-names> <surname>Nixon</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>D.Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Castellanos</surname></string-name>, <string-name><given-names>M.V.</given-names> <surname>Estrada</surname></string-name>, <string-name><given-names>P.I.</given-names> <surname>Ericsson-Gonzalez</surname></string-name>, <string-name><given-names>C.H.</given-names> <surname>Cote</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Salgado</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Sanchez</surname></string-name>, <string-name><given-names>P.T.</given-names> <surname>Dean</surname></string-name>, <string-name><given-names>S.R.</given-names> <surname>Opalenik</surname></string-name>, <string-name><given-names>D.M.</given-names> <surname>Schreeder</surname></string-name>, <string-name><given-names>D.L.</given-names> <surname>Rimm</surname></string-name>, <string-name><given-names>J.Y.</given-names> <surname>Kim</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Bordeaux</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Loi</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Horn</surname></string-name>, <string-name><given-names>M.E.</given-names> <surname>Sanders</surname></string-name>, <string-name><given-names>P.B.</given-names> <surname>Ferrell</surname>, <suffix>Jr.</suffix></string-name>, <string-name><given-names>Y.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>J.A.</given-names> <surname>Sosman</surname></string-name>, <string-name><given-names>R.S.</given-names> <surname>Davis</surname></string-name>, and <string-name><given-names>J.M.</given-names> <surname>Balko</surname></string-name>, <article-title>Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement</article-title>. <source>JCI insight</source>, <year>2018</year>. <volume>3</volume>(<issue>24</issue>): p. <fpage>e120360</fpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Sciumè</surname>, <given-names>G.</given-names></string-name>, <string-name><given-names>G.</given-names> <surname>De Angelis</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Benigni</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Ponzetta</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Morrone</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Santoni</surname></string-name>, and <string-name><given-names>G.</given-names> <surname>Bernardini</surname></string-name>, <article-title>CX3CR1 expression defines 2 KLRG1+ mouse NK-cell subsets with distinct functional properties and positioning in the bone marrow</article-title>. <source>Blood</source>, <year>2011</year>. <volume>117</volume>(<issue>17</issue>): p. <fpage>4467</fpage>–<lpage>4475</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Böttcher</surname>, <given-names>J.P.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Beyer</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Meissner</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Abdullah</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Sander</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Höchst</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Eickhoff</surname></string-name>, <string-name><given-names>J.C.</given-names> <surname>Rieckmann</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Russo</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Bauer</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Flecken</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Giesen</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Engel</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Jung</surname></string-name>, <string-name><given-names>D.H.</given-names> <surname>Busch</surname></string-name>, <string-name><given-names>U.</given-names> <surname>Protzer</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Thimme</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Mann</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Kurts</surname></string-name>, <string-name><given-names>J.L.</given-names> <surname>Schultze</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Kastenmüller</surname></string-name>, and <string-name><given-names>P.A.</given-names> <surname>Knolle</surname></string-name>, <article-title>Functional classification of memory CD8+ T cells by CX3CR1 expression</article-title>. <source>Nature Communications</source>, <year>2015</year>. <volume>6</volume>(<issue>1</issue>): p. <fpage>8306</fpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Gerlach</surname>, <given-names>C.</given-names></string-name>, <string-name><given-names>E.A.</given-names> <surname>Moseman</surname></string-name>, <string-name><given-names>S.M.</given-names> <surname>Loughhead</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Alvarez</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>Zwijnenburg</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Waanders</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Garg</surname></string-name>, <string-name><given-names>J.C.</given-names> <surname>de la Torre</surname></string-name>, and <string-name><given-names>U.H.</given-names> <surname>von Andrian</surname></string-name>, <article-title>The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and Homeostasis</article-title>. <source>Immunity</source>, <year>2016</year>. <volume>45</volume>(<issue>6</issue>): p. <fpage>1270</fpage>–<lpage>1284</lpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Yamauchi</surname>, <given-names>T.</given-names></string-name>, <string-name><given-names>T.</given-names> <surname>Hoki</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Oba</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Jain</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Attwood</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Battaglia</surname></string-name>, <string-name><given-names>S.</given-names> <surname>George</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Chatta</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Puzanov</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Morrison</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Odunsi</surname></string-name>, <string-name><given-names>B.H.</given-names> <surname>Segal</surname></string-name>, <string-name><given-names>G.K.</given-names> <surname>Dy</surname></string-name>, <string-name><given-names>M.S.</given-names> <surname>Ernstoff</surname></string-name>, and <string-name><given-names>F.</given-names> <surname>Ito</surname></string-name>, <article-title>T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors</article-title>. <source>Nature Communications</source>, <year>2021</year>. <volume>12</volume>(<issue>1</issue>): p. <fpage>1402</fpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Yan</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>S.</given-names> <surname>Cao</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>S.M.</given-names> <surname>Harrington</surname></string-name>, <string-name><given-names>W.E.</given-names> <surname>Bindeman</surname></string-name>, <string-name><given-names>A.A.</given-names> <surname>Adjei</surname></string-name>, <string-name><given-names>J.S.</given-names> <surname>Jang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Jen</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Chanana</surname></string-name>, <string-name><given-names>A.S.</given-names> <surname>Mansfield</surname></string-name>, <string-name><given-names>S.S.</given-names> <surname>Park</surname></string-name>, <string-name><given-names>S.N.</given-names> <surname>Markovic</surname></string-name>, <string-name><given-names>R.S.</given-names> <surname>Dronca</surname></string-name>, and <string-name><given-names>H.</given-names> <surname>Dong</surname></string-name>, <article-title>CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy</article-title>. <source>JCI Insight</source>, <year>2018</year>. <volume>3</volume>(<issue>8</issue>).</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Urban</surname>, <given-names>S.L.</given-names></string-name>, <string-name><given-names>I.J.</given-names> <surname>Jensen</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Shan</surname></string-name>, <string-name><given-names>L.L.</given-names> <surname>Pewe</surname></string-name>, <string-name><given-names>H.-H.</given-names> <surname>Xue</surname></string-name>, <string-name><given-names>V.P.</given-names> <surname>Badovinac</surname></string-name>, and <string-name><given-names>J.T.</given-names> <surname>Harty</surname></string-name>, <article-title>Peripherally induced brain tissue–resident memory CD8+ T cells mediate protection against CNS infection</article-title>. <source>Nature Immunology</source>, <year>2020</year>. <volume>21</volume>(<issue>8</issue>): p. <fpage>938</fpage>–<lpage>949</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Mackay</surname>, <given-names>L.K.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Minnich</surname></string-name>, <string-name><given-names>N.A.</given-names> <surname>Kragten</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Liao</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Nota</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Seillet</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Zaid</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Man</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Preston</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Freestone</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Braun</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Wynne-Jones</surname></string-name>, <string-name><given-names>F.M.</given-names> <surname>Behr</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Stark</surname></string-name>, <string-name><given-names>D.G.</given-names> <surname>Pellicci</surname></string-name>, <string-name><given-names>D.I.</given-names> <surname>Godfrey</surname></string-name>, <string-name><given-names>G.T.</given-names> <surname>Belz</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Pellegrini</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Gebhardt</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Busslinger</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Shi</surname></string-name>, <string-name><given-names>F.R.</given-names> <surname>Carbone</surname></string-name>, <string-name><given-names>R.A.</given-names> <surname>van Lier</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Kallies</surname></string-name>, and <string-name><given-names>K.P.</given-names> <surname>van Gisbergen</surname></string-name>, <article-title>Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes</article-title>. <source>Science</source>, <year>2016</year>. <volume>352</volume>(<issue>6284</issue>): p. <fpage>459</fpage>–<lpage>63</lpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Ma</surname>, <given-names>J.</given-names></string-name>, <string-name><given-names>B.</given-names> <surname>Zheng</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Goswami</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Meng</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Cao</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Duan</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Gao</surname></string-name>, and <string-name><given-names>X.</given-names> <surname>Zhang</surname></string-name>, <article-title>PD1(Hi) CD8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma</article-title>. <source>Journal for immunotherapy of cancer</source>, <year>2019</year>. <volume>7</volume>(<issue>1</issue>): p. <fpage>331</fpage>–<lpage>331</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><given-names>C.</given-names> <surname>Liu</surname></string-name>, X.,Y. <string-name><surname>Wang</surname>, <given-names>H</given-names></string-name>. <string-name><surname>Lu</surname>, <given-names>J</given-names></string-name>. <string-name><surname>Li</surname>, <given-names>X</given-names></string-name>. <string-name><surname>Yan</surname>, <given-names>M.</given-names></string-name> <string-name><surname>Xiao</surname>, <given-names>J.</given-names></string-name> <string-name><surname>Hao</surname>, <given-names>A.</given-names></string-name> <string-name><surname>Alekseev</surname>, <given-names>H.</given-names></string-name> <string-name><surname>Khong</surname>, <given-names>T.</given-names></string-name> <string-name><surname>Chen</surname>, <given-names>R.</given-names></string-name> <string-name><surname>Huang</surname>, <given-names>J.</given-names></string-name> <string-name><surname>Wu</surname>, <given-names>Q.</given-names></string-name> <string-name><surname>Zhao</surname>, <given-names>Q.</given-names></string-name> <string-name><surname>Wu</surname>, <given-names>S.</given-names></string-name> <string-name><surname>Xu</surname>, <given-names>X.</given-names></string-name> <string-name><surname>Wang</surname>, <given-names>W.</given-names></string-name> <string-name><surname>Jin</surname>, <given-names>S.</given-names></string-name> <string-name><surname>Yu</surname>, <given-names>Y.</given-names></string-name> <string-name><surname>Wang</surname>, <given-names>L.</given-names></string-name> <string-name><surname>Wei</surname>, <given-names>A.</given-names></string-name> <string-name><surname>Wang</surname>, <given-names>B.</given-names></string-name> <string-name><surname>Zhong</surname>, <given-names>L.</given-names></string-name> <string-name><surname>Ni</surname>, <given-names>X.</given-names></string-name> <string-name><surname>Liu</surname>, <given-names>R.</given-names></string-name> <string-name><surname>Nurieva</surname>, <given-names>L.</given-names></string-name> <string-name><surname>Ye</surname>, <given-names>Q.</given-names></string-name> <string-name><surname>Tian</surname>, <given-names>X.-W.</given-names></string-name> <string-name><surname>Bian</surname></string-name>, and <string-name><surname>Dong</surname></string-name>, <article-title>Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction</article-title>. <source>Nature</source>, <year>2019</year>. <volume>567</volume>(<issue>7749</issue>): p. <fpage>525</fpage>–<lpage>529</lpage>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Dan</surname>, <given-names>L.</given-names></string-name>, <string-name><given-names>L.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Song</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Yin</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Qi</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Hu</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Hu</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Ji</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Jin</surname></string-name>, <string-name><given-names>M.A.</given-names> <surname>McNutt</surname></string-name>, and <string-name><given-names>Y.</given-names> <surname>Yin</surname></string-name>, <article-title>The phosphatase PAC1 acts as a T cell suppressor and attenuates host antitumor immunity</article-title>. <source>Nature Immunology</source>, <year>2020</year>. <volume>21</volume>(<issue>3</issue>): p. <fpage>287</fpage>–<lpage>297</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Bignon</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>A.</given-names> <surname>Régent</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Klipfel</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Desnoyer</surname></string-name>, <string-name><given-names>P.</given-names> <surname>de la Grange</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Martinez</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Lortholary</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Dalloul</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Mouthon</surname></string-name>, and <string-name><given-names>K.</given-names> <surname>Balabanian</surname></string-name>, <article-title>DUSP4-mediated accelerated T-cell senescence in idiopathic CD4 lymphopenia</article-title>. <source>Blood</source>, <year>2015</year>. <volume>125</volume>(<issue>16</issue>): p. <fpage>2507</fpage>–<lpage>18</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Maine</surname>, <given-names>C.J.</given-names></string-name>, <string-name><given-names>J.R.</given-names> <surname>Teijaro</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Marquardt</surname></string-name>, and <string-name><given-names>L.A.</given-names> <surname>Sherman</surname></string-name>, <article-title>PTPN22 contributes to exhaustion of T lymphocytes during chronic viral infection</article-title>. <source>Proceedings of the National Academy of Sciences</source>, <year>2016</year>. <volume>113</volume>(<issue>46</issue>): p. <fpage>E7231</fpage>–<lpage>E7239</lpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname>, <given-names>H.</given-names></string-name>, <string-name><given-names>A.M.</given-names> <surname>van der Leun</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Yofe</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Lubling</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Gelbard-Solodkin</surname></string-name>, <string-name><given-names>A.C.J.</given-names> <surname>van Akkooi</surname></string-name>, <string-name><given-names>M.</given-names> <surname>van den Braber</surname></string-name>, <string-name><given-names>E.A.</given-names> <surname>Rozeman</surname></string-name>, <string-name><given-names>J.B.A.G.</given-names> <surname>Haanen</surname></string-name>, <string-name><given-names>C.U.</given-names> <surname>Blank</surname></string-name>, <string-name><given-names>H.M.</given-names> <surname>Horlings</surname></string-name>, <string-name><given-names>E.</given-names> <surname>David</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Baran</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Bercovich</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Lifshitz</surname></string-name>, <string-name><given-names>T.N.</given-names> <surname>Schumacher</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Tanay</surname></string-name>, and <string-name><given-names>I.</given-names> <surname>Amit</surname></string-name>, <article-title>Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma</article-title>. <source>Cell</source>, <year>2019</year>. <volume>176</volume>(<issue>4</issue>): p. <fpage>775</fpage>–<lpage>789</lpage>.e18.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Jin</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>C.F.</given-names> <surname>Guerrero-Juarez</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Chang</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Ramos</surname></string-name>, <string-name><given-names>C.-H.</given-names> <surname>Kuan</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Myung</surname></string-name>, <string-name><given-names>M.V.</given-names> <surname>Plikus</surname></string-name>, and <string-name><given-names>Q.</given-names> <surname>Nie</surname></string-name>, <article-title>Inference and analysis of cell-cell communication using CellChat</article-title>. <source>Nature Communications</source>, <year>2021</year>. <volume>12</volume>(<issue>1</issue>): p. <fpage>1088</fpage>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Wei</surname>, <given-names>J.</given-names></string-name>, <string-name><given-names>A.</given-names> <surname>Marisetty</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Schrand</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Gabrusiewicz</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Hashimoto</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Ott</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Grami</surname></string-name>, <string-name><given-names>L.Y.</given-names> <surname>Kong</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Ling</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Caruso</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>Y.A.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>G.N.</given-names> <surname>Fuller</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Huse</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Gilboa</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Kang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Huang</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Verhaak</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Li</surname></string-name>, and <string-name><given-names>A.B.</given-names> <surname>Heimberger</surname></string-name>, <article-title>Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target</article-title>. <source>J Clin Invest</source>, <year>2019</year>. <volume>129</volume>(<issue>1</issue>): p. <fpage>137</fpage>–<lpage>149</lpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Klement</surname>, <given-names>J.D.</given-names></string-name>, <string-name><given-names>A.V.</given-names> <surname>Paschall</surname></string-name>, <string-name><given-names>P.S.</given-names> <surname>Redd</surname></string-name>, <string-name><given-names>M.L.</given-names> <surname>Ibrahim</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Lu</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Celis</surname></string-name>, <string-name><given-names>S.I.</given-names> <surname>Abrams</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Ozato</surname></string-name>, and <string-name><given-names>K.</given-names> <surname>Liu</surname></string-name>, <article-title>An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion</article-title>. <source>J Clin Invest</source>, <year>2018</year>. <volume>128</volume>(<issue>12</issue>): p. <fpage>5549</fpage>–<lpage>5560</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Olah</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>V.</given-names> <surname>Menon</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Habib</surname></string-name>, <string-name><given-names>M.F.</given-names> <surname>Taga</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>C.J.</given-names> <surname>Yung</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Cimpean</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Khairallah</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Coronas-Samano</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Sankowski</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Grün</surname></string-name>, <string-name><given-names>A.A.</given-names> <surname>Kroshilina</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Dionne</surname></string-name>, <string-name><given-names>R.A.</given-names> <surname>Sarkis</surname></string-name>, <string-name><given-names>G.R.</given-names> <surname>Cosgrove</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Helgager</surname></string-name>, <string-name><given-names>J.A.</given-names> <surname>Golden</surname></string-name>, <string-name><given-names>P.B.</given-names> <surname>Pennell</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Prinz</surname></string-name>, <string-name><given-names>J.P.G.</given-names> <surname>Vonsattel</surname></string-name>, <string-name><given-names>A.F.</given-names> <surname>Teich</surname></string-name>, <string-name><given-names>J.A.</given-names> <surname>Schneider</surname></string-name>, <string-name><given-names>D.A.</given-names> <surname>Bennett</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Regev</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Elyaman</surname></string-name>, <string-name><given-names>E.M.</given-names> <surname>Bradshaw</surname></string-name>, and <string-name><given-names>P.L.</given-names> <surname>De Jager</surname></string-name>, <article-title>Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer’s disease</article-title>. <source>Nature Communications</source>, <year>2020</year>. <volume>11</volume>(<issue>1</issue>): p. <fpage>6129</fpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Shekarian</surname>, <given-names>T.</given-names></string-name>, <string-name><given-names>C.P.</given-names> <surname>Zinner</surname></string-name>, <string-name><given-names>E.M.</given-names> <surname>Bartoszek</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Duchemin</surname></string-name>, <string-name><given-names>A.T.</given-names> <surname>Wachnowicz</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Hogan</surname></string-name>, <string-name><given-names>M.M.</given-names> <surname>Etter</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Flammer</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Paganetti</surname></string-name>, <string-name><given-names>T.A.</given-names> <surname>Martins</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Schmassmann</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Zanganeh</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Le Goff</surname></string-name>, <string-name><given-names>M.G.</given-names> <surname>Muraro</surname></string-name>, <string-name><given-names>M.-F.</given-names> <surname>Ritz</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Phillips</surname></string-name>, <string-name><given-names>S.S.</given-names> <surname>Bhate</surname></string-name>, <string-name><given-names>G.L.</given-names> <surname>Barlow</surname></string-name>, <string-name><given-names>G.P.</given-names> <surname>Nolan</surname></string-name>, <string-name><given-names>C.M.</given-names> <surname>Schürch</surname></string-name>, and <string-name><given-names>G.</given-names> <surname>Hutter</surname></string-name>, <article-title>Immunotherapy of glioblastoma explants induces interferon-&amp;#x3b3; responses and spatial immune cell rearrangements in tumor center, but not periphery</article-title>. <source>Science Advances</source>, <year>2022</year>. <volume>8</volume>(<issue>26</issue>): p. <fpage>eabn9440</fpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Smolders</surname>, <given-names>J.</given-names></string-name>, <string-name><given-names>K.M.</given-names> <surname>Heutinck</surname></string-name>, <string-name><given-names>N.L.</given-names> <surname>Fransen</surname></string-name>, <string-name><given-names>E.B.M.</given-names> <surname>Remmerswaal</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Hombrink</surname></string-name>, <string-name><given-names>I.J.M.</given-names> <surname>ten Berge</surname></string-name>, <string-name><given-names>R.A.W.</given-names> <surname>van Lier</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Huitinga</surname></string-name>, and <string-name><given-names>J.</given-names> <surname>Hamann</surname></string-name>, <article-title>Tissue-resident memory T cells populate the human brain</article-title>. <source>Nature Communications</source>, <year>2018</year>. <volume>9</volume>(<issue>1</issue>): p. <fpage>4593</fpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Kumar</surname>, <given-names>B.V.</given-names></string-name>, <string-name><given-names>W.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Miron</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Granot</surname></string-name>, <string-name><given-names>R.S.</given-names> <surname>Guyer</surname></string-name>, <string-name><given-names>D.J.</given-names> <surname>Carpenter</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Senda</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>S.H.</given-names> <surname>Ho</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Lerner</surname></string-name>, <string-name><given-names>A.L.</given-names> <surname>Friedman</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Shen</surname></string-name>, and <string-name><given-names>D.L.</given-names> <surname>Farber</surname></string-name>, <article-title>Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites</article-title>. <source>Cell Rep</source>, <year>2017</year>. <volume>20</volume>(<issue>12</issue>): p. <fpage>2921</fpage>–<lpage>2934</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Mackay</surname>, <given-names>L.K.</given-names></string-name>, <string-name><given-names>A.</given-names> <surname>Rahimpour</surname></string-name>, <string-name><given-names>J.Z.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Collins</surname></string-name>, <string-name><given-names>A.T.</given-names> <surname>Stock</surname></string-name>, <string-name><given-names>M.L.</given-names> <surname>Hafon</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Vega-Ramos</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Lauzurica</surname></string-name>, <string-name><given-names>S.N.</given-names> <surname>Mueller</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Stefanovic</surname></string-name>, <string-name><given-names>D.C.</given-names> <surname>Tscharke</surname></string-name>, <string-name><given-names>W.R.</given-names> <surname>Heath</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Inouye</surname></string-name>, <string-name><given-names>F.R.</given-names> <surname>Carbone</surname></string-name>, and <string-name><given-names>T.</given-names> <surname>Gebhardt</surname></string-name>, <article-title>The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin</article-title>. <source>Nat Immunol</source>, <year>2013</year>. <volume>14</volume>(<issue>12</issue>): p. <fpage>1294</fpage>–<lpage>301</lpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Gandoglia</surname>, <given-names>I.</given-names></string-name>, <string-name><given-names>F.</given-names> <surname>Ivaldi</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Carrega</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Armentani</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Ferlazzo</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Mancardi</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Kerlero de Rosbo</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Uccelli</surname></string-name>, and <string-name><given-names>A.</given-names> <surname>Laroni</surname></string-name>, <article-title>In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma</article-title>. <source>Immunology Letters</source>, <year>2017</year>. <volume>181</volume>: p. <fpage>109</fpage>–<lpage>115</lpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Sankowski</surname>, <given-names>R.</given-names></string-name>, <string-name><given-names>C.</given-names> <surname>Böttcher</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Masuda</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Geirsdottir</surname></string-name>, <string-name><surname>Sagar</surname>, <given-names>E.</given-names></string-name> <string-name><surname>Sindram</surname>, <given-names>T.</given-names></string-name> <string-name><surname>Seredenina</surname>, <given-names>A.</given-names></string-name> <string-name><surname>Muhs</surname>, <given-names>C.</given-names></string-name> <string-name><surname>Scheiwe</surname>, <given-names>M.J.</given-names></string-name> <string-name><surname>Shah</surname>, <given-names>D.H.</given-names></string-name> <string-name><surname>Heiland</surname>, <given-names>O.</given-names></string-name> <string-name><surname>Schnell</surname>, <given-names>D.</given-names></string-name> <string-name><surname>Grün</surname>, <given-names>J.</given-names></string-name> <string-name><surname>Priller</surname>, and <given-names>M.</given-names></string-name> <string-name><surname>Prinz</surname></string-name>, <article-title>Mapping microglia states in the human brain through the integration of high-dimensional techniques</article-title>. <source>Nature Neuroscience</source>, <year>2019</year>. <volume>22</volume>(<issue>12</issue>): p. <fpage>2098</fpage>–<lpage>2110</lpage>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Kilian</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>R.</given-names> <surname>Sheinin</surname></string-name>, <string-name><given-names>C.L.</given-names> <surname>Tan</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Friedrich</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Krämer</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Kaminitz</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Sanghvi</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Lindner</surname></string-name>, <string-name><given-names>Y.-C.</given-names> <surname>Chih</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Cichon</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Richter</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Jung</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Jähne</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Ratliff</surname></string-name>, <string-name><given-names>R.M.</given-names> <surname>Prins</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Etminan</surname></string-name>, <string-name><given-names>A.</given-names> <surname>von Deimling</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Wick</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Madi</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Bunse</surname></string-name>, and <string-name><given-names>M.</given-names> <surname>Platten</surname></string-name>, <article-title>MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors</article-title>. <source>Cancer Cell</source>, <year>2023</year>. <volume>41</volume>(<issue>2</issue>): p. <fpage>235</fpage>–<lpage>251</lpage>.e9.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Srivastava</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>L.</given-names> <surname>Malik</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Smith</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Sudbery</surname></string-name>, and <string-name><given-names>R.</given-names> <surname>Patro</surname></string-name>, <article-title>Alevin efficiently estimates accurate gene abundances from dscRNA-seq data</article-title>. <source>Genome Biol</source>, <year>2019</year>. <volume>20</volume>(<issue>1</issue>): p. <fpage>65</fpage>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Griffiths</surname>, <given-names>J.A.</given-names></string-name>, <string-name><given-names>A.C.</given-names> <surname>Richard</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Bach</surname></string-name>, <string-name><given-names>A.T.L.</given-names> <surname>Lun</surname></string-name>, and <string-name><given-names>J.C.</given-names> <surname>Marioni</surname></string-name>, <article-title>Detection and removal of barcode swapping in single-cell RNA-seq data</article-title>. <source>Nat Commun</source>, <year>2018</year>. <volume>9</volume>(<issue>1</issue>): p. <fpage>2667</fpage>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Lun</surname>, <given-names>A.T.L.</given-names></string-name>, <string-name><given-names>S.</given-names> <surname>Riesenfeld</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Andrews</surname></string-name>, <string-name><given-names>T.P.</given-names> <surname>Dao</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Gomes</surname></string-name>, <article-title>J. participants in the 1st Human Cell Atlas, and J.C. Marioni, <italic>EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data</italic></article-title>. <source>Genome Biol</source>, <year>2019</year>. <volume>20</volume>(<issue>1</issue>): p. <fpage>63</fpage>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Vallejos</surname>, <given-names>C.A.</given-names></string-name>, <string-name><given-names>D.</given-names> <surname>Risso</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Scialdone</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Dudoit</surname></string-name>, and <string-name><given-names>J.C.</given-names> <surname>Marioni</surname></string-name>, <article-title>Normalizing single-cell RNA sequencing data: challenges and opportunities</article-title>. <source>Nat Meth</source>, <year>2017</year>. <volume>14</volume>(<issue>6</issue>): p. <fpage>565</fpage>–<lpage>571</lpage>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Lun</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>D.</given-names> <surname>McCarthy</surname></string-name>, and <string-name><given-names>J.</given-names> <surname>Marioni</surname></string-name>, <article-title>A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor [version 2; referees: 3 approved, 2 approved with reservations]</article-title>. <source>F1000Research</source>, <year>2016</year>. <volume>5</volume>(<issue>2122</issue>).</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>McCarthy</surname>, <given-names>D.J.</given-names></string-name>, <string-name><given-names>K.R.</given-names> <surname>Campbell</surname></string-name>, <string-name><given-names>Q.F.</given-names> <surname>Wills</surname></string-name>, and <string-name><given-names>A.T.L.</given-names> <surname>Lun</surname></string-name>, <article-title>Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R</article-title>. <source>Bioinformatics</source>, <year>2017</year>. <volume>33</volume>(<issue>8</issue>): p. <fpage>1179</fpage>–<lpage>1186</lpage>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><string-name><surname>Amezquita</surname>, <given-names>R.A.</given-names></string-name>, <string-name><given-names>A.T.L.</given-names> <surname>Lun</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Becht</surname></string-name>, <string-name><given-names>V.J.</given-names> <surname>Carey</surname></string-name>, <string-name><given-names>L.N.</given-names> <surname>Carpp</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Geistlinger</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Martini</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Rue-Albrecht</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Risso</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Soneson</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Waldron</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Pages</surname></string-name>, <string-name><given-names>M.L.</given-names> <surname>Smith</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Huber</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Morgan</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Gottardo</surname></string-name>, and <string-name><given-names>S.C.</given-names> <surname>Hicks</surname></string-name>, <article-title>Orchestrating single-cell analysis with Bioconductor</article-title>. <source>Nat Methods</source>, <year>2019</year>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><string-name><surname>Lun</surname>, <given-names>A.T.</given-names></string-name>, <string-name><given-names>D.J.</given-names> <surname>McCarthy</surname></string-name>, and <string-name><given-names>J.C.</given-names> <surname>Marioni</surname></string-name>, <article-title>A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor</article-title>. <source>F1000Res</source>, <year>2016</year>. <volume>5</volume>: p. <fpage>2122</fpage>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><string-name><surname>Lütge</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>J.</given-names> <surname>Zyprych-Walczak</surname></string-name>, <string-name><given-names>U.</given-names> <surname>Brykczynska Kunzmann</surname></string-name>, <string-name><given-names>H.L.</given-names> <surname>Crowell</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Calini</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Malhotra</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Soneson</surname></string-name>, and <string-name><given-names>M.D.</given-names> <surname>Robinson</surname></string-name>, <article-title>CellMixS: quantifying and visualizing batch effects in single-cell RNA-seq data</article-title>. <source>Life Science Alliance</source>, <year>2021</year>. <volume>4</volume>(<issue>6</issue>): p. <fpage>e202001004</fpage>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><string-name><surname>Murtagh</surname>, <given-names>F.</given-names></string-name> and <string-name><given-names>P.</given-names> <surname>Legendre</surname></string-name>, <article-title>Ward’s Hierarchical Agglomerative Clustering Method: Which Algorithms Implement Ward’s Criterion?</article-title> <source>J. Classif</source>., <year>2014</year>. <volume>31</volume>(<issue>3</issue>): p. <fpage>274</fpage>–<lpage>295</lpage>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><string-name><surname>Langfelder</surname>, <given-names>P.</given-names></string-name>, <string-name><given-names>B.</given-names> <surname>Zhang</surname></string-name>, and <string-name><given-names>S.</given-names> <surname>Horvath</surname></string-name>, <article-title>Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R</article-title>. <source>Bioinformatics</source>, <year>2008</year>. <volume>24</volume>(<issue>5</issue>): p. <fpage>719</fpage>–<lpage>20</lpage>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><string-name><surname>Hao</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>S.</given-names> <surname>Hao</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Andersen-Nissen</surname></string-name>, <string-name><given-names>W.M.</given-names> <surname>Mauck</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Zheng</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Butler</surname></string-name>, <string-name><given-names>M.J.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>Wilk</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Darby</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Zager</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Hoffman</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Stoeckius</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Papalexi</surname></string-name>, <string-name><given-names>E.P.</given-names> <surname>Mimitou</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Jain</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Srivastava</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Stuart</surname></string-name>, <string-name><given-names>L.M.</given-names> <surname>Fleming</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Yeung</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>Rogers</surname></string-name>, <string-name><given-names>J.M.</given-names> <surname>McElrath</surname></string-name>, <string-name><given-names>C.A.</given-names> <surname>Blish</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Gottardo</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Smibert</surname></string-name>, and <string-name><given-names>R.</given-names> <surname>Satija</surname></string-name>, <article-title>Integrated analysis of multimodal single-cell data</article-title>. <source>Cell</source>, <year>2021</year>. <volume>184</volume>(<issue>13</issue>): p. <fpage>3573</fpage>–<lpage>3587</lpage>.e29.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><string-name><surname>Aran</surname>, <given-names>D.</given-names></string-name>, <string-name><given-names>A.P.</given-names> <surname>Looney</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Fong</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Hsu</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Chak</surname></string-name>, <string-name><given-names>R.P.</given-names> <surname>Naikawadi</surname></string-name>, <string-name><given-names>P.J.</given-names> <surname>Wolters</surname></string-name>, <string-name><given-names>A.R.</given-names> <surname>Abate</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>Butte</surname></string-name>, and <string-name><given-names>M.</given-names> <surname>Bhattacharya</surname></string-name>, <article-title>Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage</article-title>. <source>Nat Immunol</source>, <year>2019</year>. <volume>20</volume>(<issue>2</issue>): p. <fpage>163</fpage>–<lpage>172</lpage>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><string-name><surname>Law</surname>, <given-names>C.W.</given-names></string-name>, <string-name><given-names>Y.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Shi</surname></string-name>, and <string-name><given-names>G.K.</given-names> <surname>Smyth</surname></string-name><article-title>, <italic>voom: precision weights unlock linear model analysis tools for RNA-seq read counts</italic></article-title>. <source>Genome Biology</source>, <year>2014</year>. <volume>15</volume>(<issue>2</issue>): p. <fpage>R29</fpage>.</mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><string-name><surname>Weber</surname>, <given-names>L.M.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Nowicka</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Soneson</surname></string-name>, and <string-name><given-names>M.D.</given-names> <surname>Robinson</surname></string-name><article-title>, <italic>diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering</italic></article-title>. <source>Communications Biology</source>, <year>2019</year>. <volume>2</volume>(<issue>1</issue>): p. <fpage>183</fpage>.</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><string-name><surname>Dann</surname>, <given-names>E.</given-names></string-name>, <string-name><given-names>N.C.</given-names> <surname>Henderson</surname></string-name>, <string-name><given-names>S.A.</given-names> <surname>Teichmann</surname></string-name>, <string-name><given-names>M.D.</given-names> <surname>Morgan</surname></string-name>, and <string-name><given-names>J.C.</given-names> <surname>Marioni</surname></string-name>, <article-title>Differential abundance testing on single-cell data using k-nearest neighbor graphs</article-title>. <source>Nature Biotechnology</source>, <year>2022</year>. <volume>40</volume>(<issue>2</issue>): p. <fpage>245</fpage>–<lpage>253</lpage>.</mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><string-name><surname>Junttila</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>J.</given-names> <surname>Smolander</surname></string-name>, and <string-name><given-names>L.L.</given-names> <surname>Elo</surname></string-name>, <article-title>Benchmarking methods for detecting differential states between conditions from multi-subject single-cell RNA-seq data</article-title>. <source>Briefings in Bioinformatics</source>, <year>2022</year>. <volume>23</volume>(<issue>5</issue>).</mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><string-name><surname>Lun</surname>, <given-names>A.T.L.</given-names></string-name> and <string-name><given-names>J.C.</given-names> <surname>Marioni</surname></string-name>, <article-title>Overcoming confounding plate effects in differential expression analyses of single-cell RNA-seq data</article-title>. <source>Biostatistics</source>, <year>2017</year>. <volume>18</volume>(<issue>3</issue>): p. <fpage>451</fpage>–<lpage>464</lpage>.</mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="journal"><string-name><surname>Robinson</surname>, <given-names>M.D.</given-names></string-name>, <string-name><given-names>D.J.</given-names> <surname>McCarthy</surname></string-name>, and <string-name><given-names>G.K.</given-names> <surname>Smyth</surname></string-name>, <article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title>. <source>Bioinformatics</source>, <year>2010</year>. <volume>26</volume>(<issue>1</issue>): p. <fpage>139</fpage>–<lpage>140</lpage>.</mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><string-name><surname>Robinson</surname>, <given-names>M.D.</given-names></string-name> and <string-name><given-names>A.</given-names> <surname>Oshlack</surname></string-name>, <article-title>A scaling normalization method for differential expression analysis of RNA-seq data</article-title>. <source>Genome Biol</source>, <year>2010</year>. <volume>11</volume>(<issue>3</issue>): p. <fpage>R25</fpage>.</mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><string-name><surname>Love</surname>, <given-names>M.I.</given-names></string-name>, <string-name><given-names>W.</given-names> <surname>Huber</surname></string-name>, and <string-name><given-names>S.</given-names> <surname>Anders</surname></string-name>, <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biology</source>, <year>2014</year>. <volume>15</volume>(<issue>12</issue>): p. <fpage>550</fpage>.</mixed-citation></ref>
<ref id="c82"><label>82.</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname>, <given-names>D.</given-names></string-name> and <string-name><given-names>G.K.</given-names> <surname>Smyth</surname></string-name>, <article-title>Camera: a competitive gene set test accounting for inter-gene correlation</article-title>. <source>Nucleic Acids Res</source>, <year>2012</year>. <volume>40</volume>(<issue>17</issue>): p. <fpage>e133</fpage>.</mixed-citation></ref>
<ref id="c83"><label>83.</label><mixed-citation publication-type="journal"><string-name><surname>Subramanian</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>P.</given-names> <surname>Tamayo</surname></string-name>, <string-name><given-names>V.K.</given-names> <surname>Mootha</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Mukherjee</surname></string-name>, <string-name><given-names>B.L.</given-names> <surname>Ebert</surname></string-name>, <string-name><given-names>M.A.</given-names> <surname>Gillette</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Paulovich</surname></string-name>, <string-name><given-names>S.L.</given-names> <surname>Pomeroy</surname></string-name>, <string-name><given-names>T.R.</given-names> <surname>Golub</surname></string-name>, <string-name><given-names>E.S.</given-names> <surname>Lander</surname></string-name>, and <string-name><given-names>J.P.</given-names> <surname>Mesirov</surname></string-name>, <article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc Natl Acad Sci U S A</source>, <year>2005</year>. <volume>102</volume>(<issue>43</issue>): p. <fpage>15545</fpage>–<lpage>15550</lpage>.</mixed-citation></ref>
</ref-list>
<ack>
<title>Acknowledgements</title>
<p>We are grateful to the patients and their families for their consent to donate tissue to our brain tumor biobank. We thank Tamara Hüssen, Alison Riberio and Florian Limani for experimental support and Cecile Buenter for critical revision of the manuscript. Calculations were performed at sciCORE (<ext-link ext-link-type="uri" xlink:href="http://scicore.unibas.ch/">http://scicore.unibas.ch/</ext-link>) scientific computing center at the University of Basel.</p>
</ack>
<sec id="s6">
<title>Author contribution</title>
<p>G.H., S. Herter, M.B., S.D. and P.S., conceived and planned the project. J.R. and S. Hogan analyzed the scRNA-sequencing data and performed statistical analysis. P.S. and S.D. performed experiments and interpreted the results. T.S., T.A.M. and M.-F.R. helped coordinating experiments. P.S. wrote the manuscript. G.H. supervised and coordinated the study and critically revised the manuscript. All authors reviewed the paper and approved its final version.</p>
</sec>
<sec id="s7">
<title>Competing interests</title>
<p>G.H. has equity in, and is a cofounder of Incephalo Inc. S.D., S.H. and M.B. are affiliated with Roche Pharmaceutical Research and Early Development. The authors have no financial interests to declare.</p>
</sec>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.92678.1.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ng</surname>
<given-names>Tony</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>King's College London</institution>
</institution-wrap>
<city>London</city>
<country>United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Convincing</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>This study is <bold>valuable</bold> and contains results that are supported by <bold>convincing</bold> evidence. In the future, the observations could be further strengthened by independent validation, and by looking at larger numbers of patients, as well as by determining whether patient heterogeneity is either contributing to or obscuring certain patterns. The work will be of interest to a broad audience in the oncology and immunology fields as it is on a cancer type that does not respond well to immune checkpoint therapeutics.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.92678.1.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>
In this manuscript, Schmassmann et al. present a study on the immune microenvironment of grade 4 gliomas using single-cell RNA-seq data from the tumor center, periphery, and peripheral blood of patients. This manuscript is overall well written and reads easily. The approach to studying the TME at various spatial locations is innovative and interesting, and the dataset presented has the potential to become a useful resource for the community. However, the size of the dataset, notably in the context of the important inter-patient variability on key clinical information, hinders the generalizability of the results. The analysis presented by the authors seems at times somewhat shallow as compared to other studies in the literature, being almost solely based on the analysis of a single dataset with extremely limited biological validation of the observations, and some claims made by the authors do not seem appropriately backed by the data they present. While I appreciate the vast analysis effort undertaken by the authors, it seems more work is required to make the most of this interesting dataset and substantiate the conclusions.</p>
<p>Strengths:</p>
<p>
The authors have provided useful insights into diverse GBMs (IDH mutant and IDH wild-type) that provide a deep assessment of individual tumors with spatial information.</p>
<p>Weaknesses:</p>
<p>
A larger set of tumors will need to be explored before general principles of immune biology and GBM immune evasion can be uncovered. This is a descriptive study that provides some interesting new hypotheses - but these will need deeper functional exploration.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.92678.1.sa0</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>
Most of this paper concerns scRNA-seq data generated from glioblastoma patients, from three regions: tumor center, tumor periphery, and peripheral blood mononuclear cells. They focus on immune cells, and especially microglia and T-cells, where they look at the presence/absence/changes in different types of immune signatures. The data and analysis are sound and supportive of the conclusions they draw, though future studies with more patients and/or low-throughput validation would strengthen their evidence. This study adds to our knowledge of the immune cell environment in glioblastoma patients and its regional variation.</p>
<p>Strengths:</p>
<p>
A key strength of the paper lies in the novelty of the data, which simultaneously examines, at single-cell resolution, gene expression in two different tumor regions (center and periphery) along with peripheral blood. The authors provide numerous detailed and state-of-the-art analyses of this data, including gene differential expression, differential abundance of cell types, gene ontology analyses, tSNE visualizations, etc.</p>
<p>They focus in particular on differences in immune cell types. There are some suggestive differences in immune cell composition of center versus periphery, although the number of patients (5, one of whom is missing center data) does not allow one to draw a definitive conclusion.</p>
<p>They identified more definitive gene expression differences in center versus peripheral microglia -- differences that were not reflected in other cell types, and which included downregulation of a number of immune response functions. They also identified gene expression differences between two subsets of microglia, although those may partly reflect regional differences (the subsets are differentially enriched in the center versus periphery) or differential representation of different patients.</p>
<p>Finally, they identify differences in CD8+ T cells and NK cells in the center versus the periphery, where the latter were less activated/proliferative/cytotoxic.</p>
<p>Data analysis is performed to a high standard, using best-available methods and in some cases backed up with alternative approaches showing similar results.</p>
<p>Weaknesses:</p>
<p>
While the nature of the dataset is novel, the relatively low patient numbers (five) and patient diversity (e.g. with regard to IHD1 status) may be obscuring differences in cell type abundances or cell state between regions.</p>
<p>Most discoveries based on the scRNA-seq discussed in the paper remain to be validated by low-throughput methods in either the same patient samples, if material remains, or in other patients.</p>
</body>
</sub-article>
</article>